



NCCN
GUIDELINES
FOR PATIENTS®

2022

Rectal Cancer

Presented with
support from:



NATIONAL COMPREHENSIVE CANCER NETWORK®
FOUNDATION
Guiding Treatment. Changing Lives.

ACF ANAL
CANCER
FOUNDATION



colorectal
cancer
alliance
Tomorrow can't wait

FIGHT
★
COLORECTAL CANCER



Available online at [NCCN.org/patients](https://www.nccn.org/patients)



**It's easy to
get lost in
the cancer
world**



**Let NCCN
Guidelines
for Patients[®]
be your guide**


- ✓ Step-by-step guides to the cancer care options likely to have the best results
- ✓ Based on treatment guidelines used by health care providers worldwide
- ✓ Designed to help you discuss cancer treatment with your doctors

Rectal Cancer



National Comprehensive
Cancer Network®

NCCN Guidelines for Patients® are developed by the National Comprehensive Cancer Network® (NCCN®)



NCCN

- ✓ An alliance of leading cancer centers across the United States devoted to patient care, research, and education

**Cancer centers
that are part of NCCN:**
[NCCN.org/cancercenters](https://www.nccn.org/cancercenters)



NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

- ✓ Developed by experts from NCCN cancer centers using the latest research and years of experience
- ✓ For providers of cancer care all over the world
- ✓ Expert recommendations for cancer screening, diagnosis, and treatment

Free online at
[NCCN.org/guidelines](https://www.nccn.org/guidelines)



NCCN Guidelines for Patients

- ✓ Present information from the NCCN Guidelines in an easy-to-learn format
- ✓ For people with cancer and those who support them
- ✓ Explain the cancer care options likely to have the best results

Free online at
[NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines)

These NCCN Guidelines for Patients are based on the NCCN Guidelines® for Rectal Cancer, Version 2.2022 — September 20, 2022

© 2022 National Comprehensive Cancer Network, Inc. All rights reserved. NCCN Guidelines for Patients and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. No one, including doctors or patients, may use the NCCN Guidelines for Patients for any commercial purpose and may not claim, represent, or imply that the NCCN Guidelines for Patients that have been modified in any manner are derived from, based on, related to, or arise out of the NCCN Guidelines for Patients. The NCCN Guidelines are a work in progress that may be redefined as often as new significant data become available. NCCN makes no warranties of any kind whatsoever regarding its content, use, or application and disclaims any responsibility for its application or use in any way.

NCCN Foundation seeks to support the millions of patients and their families affected by a cancer diagnosis by funding and distributing NCCN Guidelines for Patients. NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising doctors at the center of innovation in cancer research. For more details and the full library of patient and caregiver resources, visit [NCCN.org/patients](https://www.nccn.org/patients).

National Comprehensive Cancer Network (NCCN) / NCCN Foundation
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462
215.690.0300



NCCN Guidelines for Patients are supported by funding from the NCCN Foundation®

To make a gift or learn more, please visit [NCCNFoundation.org/donate](https://www.nccnfoundations.org/donate) or e-mail PatientGuidelines@NCCN.org.

Additional support provided by



The Anal Cancer Foundation (ACF) is dedicated to ending anal cancer and improving the lives of those affected by it. ACF programs raise awareness, accelerate early detection, improve quality of life, and support research to find a cure. ACF is proud to partner with the NCCN Foundation to provide this comprehensive, evidence-based guide to support rectal cancer patients and their loved ones. For help during any stage of your journey, please visit [analcancerfoundation.org](https://www.analcancerfoundation.org).



The Colorectal Cancer Alliance is the largest nonprofit advocacy organization dedicated to colorectal cancer. The Alliance empowers a nation of allies who work with us to support patients and families, caregivers, and survivors; to raise awareness of preventive measures; and inspire efforts to fund critical research. Call the toll-free Helpline for support and resources: 877.422.2030 [ccalliance.org](https://www.ccalliance.org)



Fight Colorectal Cancer We fight to cure colorectal cancer and serve as relentless champions of hope for all affected by this disease through informed patient support, impactful policy change, and breakthrough research endeavors. As an organization dedicated to helping the community find trusted resources to make informed decisions about their health, we are proud to support this comprehensive resource. [fightcolorectalcancer.org](https://www.fightcolorectalcancer.org)



Contents

6	Rectal cancer basics
14	Treatment planning
25	Overview of treatments
40	Non-metastatic cancer
50	Metastatic cancer
57	Survivorship
63	Making treatment decisions
70	Words to know
73	NCCN Contributors
74	NCCN Cancer Centers
76	Index

1

Rectal cancer basics

7 The rectum

8 Polyps

8 Staging

13 Key points



Rectal cancer is a common and highly treatable cancer. Advances in screening and treatment have led to better outcomes for patients. This chapter provides some basic information about rectal cancer that will help prepare you for treatment.

The rectum


The rectum is the last several inches of the large intestine, also known as the large bowel. The large bowel is a long tube-shaped organ that forms the last part of the digestive system. The digestive system breaks down food for the body to use.

After being swallowed, food passes through the esophagus and into the stomach, where it is turned into a liquid. From the stomach, food enters the small bowel. Here, food is broken down into very small parts to allow nutrients to be absorbed into the bloodstream.

Partly digested food then moves into the large bowel. The colon is the first and longest section of the large bowel. The colon turns unused food from a liquid into a solid by absorbing water. This solid, unused food is called feces or stool. Stool is then held in the rectum until it exits the body through an opening called the anus.

The rectum

The rectum is about 5 inches (12 centimeters) long and forms the last part of the large bowel. Stool is held in the rectum until it leaves the body through the anus.



© 2022 Terese Winslow LLC
U.S. Govt. has certain rights


Polyps

A polyp is an overgrowth of cells on the inner lining of the rectal wall. There are different types of polyps. Some are more likely to turn into cancer than others. The most common type is called an adenoma. Adenomas are considered pre-cancerous. While it may take many years, adenomas can become invasive rectal cancer. Cancer that forms in an adenoma is known as an adenocarcinoma. Adenocarcinoma is the most common type of rectal cancer.

Polyps need to be removed and tested for cancer. While most polyps do not become cancer, almost all rectal cancers start in a polyp. Removing polyps can prevent cancer before it occurs. Polyps can also be tested to make sure that cancer has not already started to develop. Most polyps can be removed during a colonoscopy, using a minor surgical procedure called a polypectomy.

More information on rectal cancer that forms in a polyp is provided in *Part 4: Non-metastatic cancer*.

For information on screening for colorectal cancer, see the *NCCN Guidelines for Patients: Colorectal Cancer Screening* at [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines).



Staging

The stage describes the extent of cancer in the body and helps determine the amount of treatment you need. It is used to plan which tests may be needed and which treatments are best for you. Having a general idea of the structure of the rectal wall is helpful for understanding how rectal cancer is staged.

The rectal wall is made of layers of tissue. Cancer starts in the innermost layer that comes in contact with food. This layer is called the mucosa. The next layer is the submucosa. It is made of connective tissue and contains mucus glands, blood and lymph vessels, and nerves. The submucosa is followed by a layer of muscle called the muscularis propria. While the colon has an extra fourth layer called serosa (or adventitia), much of the rectum does not have this outer layer. This can make it easier for rectal cancer to spread to nearby areas in the pelvis.

If left untreated, cancer cells grow through the layers of the rectal wall, towards the inside of the pelvis. The cancer can then invade structures or organs outside of the rectum. Cancer cells can also break off from the rectal tumor and travel through lymph or blood to nearby lymph nodes.

The American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) system is used to stage rectal cancer. In the AJCC system, the following key pieces of information about the cancer are used to give it a stage:

- **T:** How far the tumor has grown into or through the rectal wall
- **N:** Whether any lymph nodes have cancer in them

- **M:** Whether the cancer has spread to areas or organs outside the rectum (metastasized)

The T, N, and M scores are combined to assign the cancer a stage. There are five stages of rectal cancer. They are numbered 0, I (1), II (2), III (3), or IV (4). The stages are explained below.

Stage 0

There are abnormal cells on the innermost layer of the rectal wall. These abnormal cells may later invade deeper layers of the rectal wall.

Stage I

The cancer has grown into either the second layer (submucosa) or the third layer (muscularis propria) of the rectal wall. There is no cancer in nearby lymph nodes or in areas outside the rectum.

Stage II



The cancer has grown through the rectal wall and possibly into nearby tissues, structures, or organs. There is no cancer in nearby lymph nodes or in areas far from the rectum.



Stage III



The cancer has spread to nearby lymph nodes or there are tumor deposits. Tumor deposits are small tumors in the fat around the rectum. Cancer has not spread to areas far from the rectum.

Stage IV


The cancer has spread to areas far from the rectum. Rectal cancer spreads most often to the liver and/or lungs.







Stage IV



Key points

- The rectum is the last part of the large bowel. Stool is held in the rectum until it leaves the body through the anus.
- Many rectal cancers start in polyps called adenomas.
- Cancer that forms in an adenoma is called an adenocarcinoma. Adenocarcinoma is the most common type of rectal cancer.
- After forming in a polyp, cancer can grow through the rectal wall and to other areas of the body.
- Cancer cells can spread to other body parts through lymph or blood. This is called metastasis.
- The cancer stage describes the extent of cancer in the body.
- There are five stages of rectal cancer. They are numbered 0, I (1), II (2), III (3), or IV (4).



Radiation side effects can differ from patient to patient and male to female. If you're a female patient, please talk to your doctor about intercourse after radiation treatment. How to prevent pain during intercourse after radiation may be an uncomfortable topic to discuss but it will be worth it in the end.

– Marisa

Rectal cancer survivor

2

Treatment planning

- 15 Health history
- 16 Colonoscopy
- 17 Biopsy
- 18 Pathology report
- 18 Blood tests
- 19 Imaging tests
- 22 Biomarker testing
- 23 Fertility and family planning
- 24 Key points



Your doctors will make a treatment plan just for you. First, they need to gather information about the cancer and your general health. This chapter discusses testing and other steps needed to create your treatment plan.

Health history

Your personal health history includes any health events and medicines you've taken in your life. It helps your doctors decide which treatments may be best for you. Rectal cancer and other diseases can run in families. For this reason, your doctor will ask about the medical history of your blood relatives. It is helpful to know who in your family has had what diseases and at what ages. Your doctor may ask about the health of your siblings, your parents and their siblings, and your grandparents and their siblings.

Inherited cancer syndromes

Rectal cancer most often occurs for unknown reasons. Some people, however, are more likely to get rectal cancer than the average person. This is because a mutation in their DNA was passed down to them, causing a disorder that increases the risk of rectal cancer. This is called an inherited cancer syndrome. Most rectal cancers associated with an inherited cancer syndrome are due to either Lynch syndrome or familial adenomatous polyposis (FAP). Both are uncommon in people with rectal cancer.

If your doctor thinks you might have an inherited syndrome, you will be referred to a genetic counselor. A genetic counselor can talk with you and sometimes your family members

about getting tested for syndromes related to rectal cancer. It is important to meet with a genetic counselor before having any genetic testing. To be tested, you must provide a sample of blood or saliva. The sample is tested in a lab for changes (mutations) in genes that cause these syndromes.

Lynch syndrome

People born with Lynch syndrome are at high risk of developing colorectal cancer and some other cancers, particularly endometrial and ovarian cancers. This syndrome is caused by inherited mutations of genes that fix damaged DNA. These are called mismatch repair (MMR) genes. NCCN experts recommend testing everyone with rectal cancer for problems with the MMR genes. This helps determine who should be tested for Lynch syndrome. Only about 5 out of every 100 people with rectal cancer have Lynch syndrome. Sometimes Lynch syndrome is referred to as hereditary non-polyposis colon cancer (HNPCC), but they are not exactly the same. Specific family history criteria must be met in order for a diagnosis of HNPCC to be made.

Familial adenomatous polyposis (FAP)

FAP is a rare inherited syndrome. It can cause hundreds to thousands of polyps to form in the colon and rectum. The polyps start as non-cancerous growths, but over time they can turn into cancer. Cancer is likely to develop by age 50 in people with classic FAP. A milder form called attenuated FAP causes fewer polyps and usually starts later in life. Only about 1 in 100 people with rectal cancer have FAP.

Other syndromes

There are other, even more rare, inherited cancer syndromes. If you have a strong family history of cancers and/or young-onset

colorectal cancer, a genetics referral is a good option to learn more.

Colonoscopy

A colonoscopy is a procedure that allows your doctor to examine your colon and rectum for polyps and other diseases. A colonoscope is the device used for the test. Part of it looks like a thin tube. It has a light and camera. This part is inserted into the anus and gently guided through the large bowel.

You may be put on a liquid diet for 1 to 3 days before the test. You may also be instructed to take a laxative or an enema the night before. This will clean out your bowel. Right before the test, you may be given a sedative to lessen


any pain. You will likely wear a hospital gown. The test will be performed while you lie on your side.

To see better, gas may be pumped into your bowel to make it bigger. You may be asked to shift a little to help your doctor guide the device. A picture of your rectum will be viewed by your doctor on a screen. If a polyp is found, a cutting tool will be inserted through the tube to remove it.

A colonoscopy takes about 30 to 60 minutes. Afterward, you may stay for another hour to allow any drugs that were used to wear off. However, you'll still need someone to drive you home. Most people feel normal the next day. Contact your doctor if you have severe pain, bloody stool, vomiting, or weakness.

Colonoscopy

A colonoscopy is a procedure that allows your doctor to look for and remove any abnormal tissue from the rectum and colon. A thin device is inserted through the anus, up the rectum, and into the colon. The device has a light, a camera, and a cutting tool.



© 2022 Terese Winslow LLC
U.S. Govt. has certain rights

Biopsy

A biopsy involves removing small pieces of tissue from the rectum. The samples are sent to a pathologist for testing. A biopsy of a rectal polyp or of suspected rectal cancer is usually done during a colonoscopy.

Rectal biopsy

First, your doctor will perform a digital rectal exam (DRE). Your doctor will insert a gloved and lubricated finger into your rectum to feel your rectum and nearby tissue from various angles. An anoscope may be used to help take tissue samples near the anus. This is a round, hollow tool that has a light. It will be inserted a few inches into your rectum. There are several possible techniques that may be used for the biopsy itself. Often, biopsy forceps or a wire loop called a snare is used.

For deeper samples, a sigmoidoscope will be used. This tool has a light, camera, and attachments that can be used to remove small pieces of tissue. Tissue samples may be taken using a special brush, forceps, or a swab.


Needle biopsy

If cancer is suspected to have spread to areas outside the rectum, such as the liver or lungs, a needle may be used to do the biopsy. In this case, a computed tomography (CT) scan or ultrasound may be used to help guide the needle into the tumor to remove the tissue sample. If a very thin needle is used, it is referred to as a fine-needle aspiration (FNA) or fine-needle biopsy (FNB). If a slightly larger needle is used to remove tissue, it is called a core needle biopsy.

Digital rectal exam

In a digital rectal exam (DRE), your doctor will insert a gloved and lubricated finger into your rectum. This allows your doctor to feel your rectum and nearby tissues from various angles.

Source: <https://visualsonline.cancer.gov/details.cfm?imageid=7136>



Pathology report

Each time tissue is removed from the body and tested for cancer, the findings are detailed in a document called a pathology report. One key finding included in the report is the cancer grade. The grade is different than the cancer stage.

The cancer grade is a score of how fast the cancer is expected to grow and spread. It is based on how abnormal the cancer cells look when viewed under a microscope. Higher scores mean that the cancer is likely to grow and spread quickly. There are 5 possible grades:

- **GX** means that the grade cannot be determined.
- **G1** means that the cancer cells look similar to healthy cells. Also called well differentiated or low grade.
- **G2** means that the cancer cells are somewhat different than healthy cells. Also called moderately differentiated or intermediate grade.
- **G3** means that the cancer cells barely look like healthy cells. Also called poorly differentiated or high grade.
- **G4** means that the cancer cells are very abnormal looking. These are the highest grade and typically grow and spread faster than lower grade tumors. Also called undifferentiated or high grade.

Review your pathology report(s) with your doctor. Ask questions if you don't understand. This information can be complex. It is also a good idea to get a copy of your pathology report(s) and take notes.

Blood tests

Blood tests are used to look for signs of disease. A needle will be inserted into your vein to remove a sample of blood. The needle may bruise your skin. You may feel dizzy from the blood draw. The blood sample will be sent to a lab for testing.

Complete blood count

A complete blood count (CBC) measures the number of white blood cells, red blood cells, and platelets in a sample of blood. White blood cells help the body fight infection. Red blood cells carry oxygen throughout the body. Platelets help wounds heal by forming blood clots. Cancer and other health problems can cause low or high blood cell counts.

Chemistry profile

A chemistry profile, also called a complete metabolic panel (CMP), measures the level of certain substances in the blood. These substances include metabolites, electrolytes, and proteins. This test provides information about how well your kidneys, liver, and other organs are working.

CEA blood test

Carcinoembryonic antigen (CEA) is a protein found in blood. It is considered a tumor marker. The level of CEA is often higher than normal in people with rectal cancer, especially if the cancer has spread to other organs. Those who are pregnant or who smoke may have higher CEA levels. Monitoring CEA can be helpful even when the cancer is only in the colon and the level is normal, because the level will rise if the cancer later spreads to other organs. However, monitoring CEA is not helpful for some people, even if the cancer has spread.

Imaging tests

Imaging tests make pictures (images) of the insides of your body. They can show areas of cancer in the body. A radiologist is a doctor who is an expert in interpreting these images. Your radiologist will convey the imaging results to your cancer doctor (oncologist). This information helps your doctor plan the next steps of care.

Your treatment team will tell you how to prepare for these tests. You may need to stop taking some medicines and stop eating and drinking for a few hours before the scan.

Some imaging tests use contrast. Contrast is a substance that is injected into your bloodstream. It makes the pictures clearer. Some people have an allergic reaction to contrast. Tell your doctor if you've had problems with contrast in the past. If you

have had a reaction to a contrast agent in the past, you may be given or advised to take a steroid and an antihistamine medication (eg, Benadryl) before the scan. It will lower the risk of an allergic reaction.

Computed tomography (CT)

CT takes many pictures of areas inside of the body using x-rays. A computer combines the x-rays to make one detailed picture. The picture is saved for later viewing by a radiologist.

If surgery is needed or being considered, CT scans of your chest, abdomen, and pelvis are recommended. They can show if the cancer has spread to other structures or organs, such as the liver or lungs. Contrast should be used for CT of the abdomen and pelvis. Although contrast is not needed for the chest CT, expect to receive contrast if all three areas are

CT scans

If surgery is needed or being considered, CT scans of your chest, abdomen, and pelvis are recommended. They can show if the cancer has spread to other structures or organs, such as the liver or lungs.



being imaged at the same time. If you cannot have the contrast agent used for CT scans, magnetic resonance imaging (MRI) (described next) may be used to see the abdomen and pelvis instead.

In a few select situations, CT may be combined with positron emission tomography (PET). PET/CT is only used in select cases for rectal cancer. It may be used to help determine if surgery is an option for metastatic disease, or in the rare event that you can't receive contrast for CT or MRI. PET involves first injecting a radioactive drug (a "tracer") into the body. The radiotracer is detected with a special camera during the scan.

MRI

MRI uses a magnetic field and radio waves to make pictures of areas inside the body. MRI is especially good at making clear pictures of areas of soft tissue. Unlike a CT scan, MRI does not use radiation and is safe for most people. Patients with certain heart monitors, pacemakers, or some types of surgical clips cannot generally have MRI scanning. Tell your team if you get nervous in small spaces. This is known as claustrophobia. You may be given a sedative (medicine) to help you relax.

If surgery is needed or being considered, an MRI will be ordered to determine the extent of the cancer in the pelvis. Special techniques are used for the MRI to carefully stage the cancer using a rectal cancer staging protocol. An MRI can show how deep into the rectal wall the cancer has grown and whether there is

MRI

If surgery is needed or being considered, MRI is used to determine the extent of the cancer in the pelvis. An MRI can show how deep into the rectal wall the cancer has grown and whether there is cancer in nearby lymph nodes.



cancer in nearby lymph nodes. Contrast may or may not be used.

In addition to MRI of the pelvis, MRI may also be used to look for areas of cancer in the abdomen, especially the liver. This may be the case if you cannot receive the contrast agent used for a CT scan. If you cannot undergo an MRI scan, a CT scan of your pelvis and endorectal ultrasound may be ordered.


A gel may be inserted into the rectum before MRI imaging. A light coil device or blanket will be placed on top of you. It sends and receives radio waves to record the images. The device covers your body from below your chest to the top of your legs. Straps may be used to help you stay in place. An MRI may cause your body to feel a bit warm.

Endorectal ultrasound

Instead of pelvic MRI, you may receive an endorectal ultrasound (EUS). This test can also show the extent of cancer in the pelvis. A small probe is inserted into the rectum. The probe emits sound waves that bounce off tissue and make echoes. The echoes form a picture that can be seen by your doctor on a screen. If needed, a biopsy of lymph nodes or other structures near the rectum may be performed using EUS guidance.

Endorectal ultrasound

If you cannot have a pelvic MRI (because you have a pacemaker, for example) or if MRI images were unhelpful, you may have an endorectal ultrasound and CT of the pelvis. This test may also be ordered if your doctor knows the cancer has not grown far into the rectal wall.



Biomarker testing

Biomarkers are features of a person's cancer. Biomarkers can include proteins made in response to the cancer and non-inherited changes (mutations) in the tumor's genes.

Biomarker testing is used to learn whether your cancer has any targetable changes to help guide your treatment. If it does, targeted therapy or immunotherapy may be a treatment option if needed. The results of biomarker testing can also be used to determine whether you meet the criteria for joining certain clinical trials. Testing for biomarker mutations involves analyzing a piece of tumor tissue or a sample of blood in a lab.

Other names for biomarker testing include molecular testing, genomic testing, tumor gene testing, next-generation sequencing, and mutation testing. Biomarkers used for colorectal cancer treatment planning are described next.

For everyone with rectal cancer

MMR/MSI testing

In normal cells, a process called mismatch repair (MMR) fixes errors (mutations) that happen when the DNA divides and makes a copy of itself. If the MMR system isn't working right, errors build up and cause the DNA to become unstable. This is called microsatellite instability (MSI).

There are two kinds of lab tests for this biomarker. Depending on the method used, an abnormal result is called either microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR). Tumors that **are not** MSI-H/dMMR are referred to as microsatellite stable (MSS) or mismatch repair proficient (pMMR).

MMR or MSI testing is recommended for everyone diagnosed with rectal cancer. If the cancer is dMMR/MSI-H, you will also be tested for Lynch syndrome.

For metastatic (stage IV) rectal cancer

If rectal cancer has spread to other parts of the body, such as the liver or lungs, testing for the tumor biomarkers described next is recommended. Testing for these biomarkers may be performed individually, or as part of a larger panel (group). Testing for many biomarkers at one time is called next-generation sequencing (NGS). NGS can find other, rare gene mutations for which targeted treatments may be available.

KRAS and *NRAS* mutations

RAS is a family of genes that includes the *HRAS*, *KRAS*, and *NRAS* genes. Some rectal cancers have mutations in the *KRAS* or *NRAS* genes. These genes are often referred to as simply the "*RAS*" genes. Genes work as instruction manuals for making important proteins. As a result, the proteins these genes make are overactive and can tell the cancer to grow.

BRAF mutation

Fewer than 10 out of 100 rectal cancers have a mutation called *BRAF* V600E. This mutation may cause cancer cells to grow and spread quickly. NCCN experts recommend everyone with metastatic rectal cancer have their cancer tested for this mutation. If cancer has spread to other parts of the body and the cancer has this mutation, treatments that target abnormal *BRAF* may be helpful.

HER2 amplification

HER2 is a protein involved in normal cell growth. Having too much HER2 can cause

cancer cells to grow and spread quickly. Only about 3 to 5 out of 100 people with rectal cancer have too much HER2. HER2 testing is recommended for everyone with metastatic rectal cancer unless there is a known *RAS* or *BRAF* mutation. HER2 testing can help your doctor determine whether systemic therapies that target HER2 may help you.

Fertility and family planning

For unknown reasons, rectal cancer is being diagnosed more often in young adults. Some cancer treatments can cause or contribute to infertility. Radiation therapy, for example, is a main treatment for locally advanced rectal cancers. Radiation can damage the hormone-making function of the ovaries and testicles, causing the inability to conceive a child. Ovarian damage is known as premature ovarian insufficiency (POI) or radiation-induced premature menopause. See the *Survivorship* section of this guide for more information on this side effect.

If you want the option of having children after treatment or are unsure, tell your doctors. There are ways to be able to have children after cancer treatment. This is called fertility preservation. If you are of childbearing age, your doctor will discuss any fertility-related risks of your treatment plan with you. You may be referred for counseling about fertility preservation options. Some fertility preservation options are described next.

Sperm banking

Sperm banking stores semen for later use by freezing it in liquid nitrogen. The medical term for this is semen cryopreservation.

Egg freezing

Like sperm banking, unfertilized eggs can be removed, frozen, and stored for later use. The medical term for this is oocyte cryopreservation.


Ovarian tissue banking

This method involves removing part or all of an ovary and freezing the part that contains the eggs. The frozen tissue containing the eggs can later be unfrozen and put back in the body.

Ovarian transposition

This procedure moves one or both ovaries and fallopian tubes out of the range of the radiation beam. The medical term for this procedure is oophoropexy.

For more information on fertility and family planning, see the *NCCN Guidelines for Patients: Adolescents and Young Adults with Cancer* at [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines).



Key points

Health history

- Inherited syndromes related to rectal cancer include Lynch syndrome and FAP.
- Everyone with rectal cancer should be asked about their family health history.

Colonoscopy, biopsy, and pathology report

- A colonoscopy allows your doctor to examine your colon and rectum for polyps and lesions that may be cancerous.
- A biopsy of a rectal polyp or of suspected rectal cancer is usually done during a colonoscopy.
- Each time tissue is removed from the body and tested for cancer, the findings are detailed in a pathology report.
- One key finding included in the report is the cancer grade. The grade is a score of how fast the cancer is expected to grow and spread.

Blood tests

- A complete blood count (CBC), chemistry profile, and carcinoembryonic antigen (CEA) test are recommended blood tests for rectal cancer.

Imaging

- An MRI of the pelvis using a rectal cancer staging technique can show how deep into the rectal wall the cancer has grown and whether there is cancer in nearby lymph nodes.

- CT of the chest and abdomen (and pelvis for those who cannot have MRI) can show if the cancer has spread to the liver, lungs, or other organs.

Biomarker testing

- MMR or MSI testing is recommended for everyone diagnosed with rectal cancer.
- Testing for mutated *KRAS/NRAS* and *BRAF* genes is recommended for everyone with metastatic rectal cancer.
- HER2 testing is also recommended for everyone with metastatic rectal cancer unless there is a known *KRAS/NRAS* or *BRAF* mutation.

Fertility and family planning

- Young adults diagnosed with rectal cancer should be counseled about fertility-related risks of treatment and options for fertility preservation.
- Options for fertility preservation include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition.

3

Overview of treatments

26	Rectal surgery
30	Systemic therapy
33	Radiation therapy
35	Local therapies for metastases
37	Clinical trials
39	Key points



This chapter describes the rectal cancer treatments you may have. The specific treatments you receive will depend on the extent of the cancer, your overall health, and other factors.

Rectal surgery

This section describes the types of surgery used for rectal cancer. Another name for surgery that removes tissue, or all or part of an organ, is resection. If surgery is needed, you may have more than one type. Surgery to remove liver or lung metastases is described in the “Local therapies for metastases” section on page 35.

Your treatment team will tell you how to prepare for and what to expect during surgery. You may need to stop taking some medicines to reduce the risk of severe bleeding. Eating less, changing to a liquid diet, or using enemas or laxatives will empty your colon and rectum for surgery. Right before surgery, you will be given general anesthesia

Transanal surgery

Some small tumors that have not invaded the muscle layer of the rectum wall can be removed by transanal surgery. In staging terms, doctors describe these tumors as T1, N0, M0. This type of surgery does not require cutting into the abdomen. Instead, the rectal tumor and some surrounding tissue is removed through the anus.

A goal of surgery is to remove the tumor in one piece to avoid leaving cancer cells behind. Some normal-looking tissue around the tumor is also removed. This is called the surgical margin.

A benefit of transanal surgery is that the sphincter is not removed. The sphincter is the round muscle in the anus that opens and closes to control bowel function. Leaving the sphincter intact allows for normal bowel function and eliminates the need for a permanent colostomy bag.

A drawback to transanal surgery is that lymph nodes are not removed. You will also be watched very closely for the cancer returning. More details on transanal surgeries are given next.

Transanal local excision

This surgery removes tumors located towards the bottom of the rectum, near the anus. The surgeon cuts through all layers of the rectal wall to remove the cancer and some surrounding normal rectal tissue.

Either local or general anesthesia is used to prevent pain during surgery. Local anesthesia involves numbing the treatment site or the entire pelvis. General anesthesia uses medicines that cause a deep, sleep-like state.

Before surgery, the tumor location is confirmed with a rectal exam. Your position during surgery depends on the location of the tumor in the rectum. You may lie face down on a table that can be raised in the middle, so that your buttocks are higher than your head and feet. Or, you may lie on your back with your legs raised in stirrups.

A few tools will be used to assess the tumor. Your buttocks will be taped apart. A tool called a retractor is used to spread open the anus. A second retractor is used to expand the rectum. The surgery starts with marking the surgical margin. Your surgeon will make a dotted line around the tumor with a heated wire. The tumor will then be removed.

After removing the cancerous area and some nearby healthy tissue, the hole in the rectal wall is then closed. At the end, the surgeon will perform a proctoscopic exam to make sure the rectum was not closed or narrowed. A proctoscopic exam involves examining the rectum with a short, rigid tool called a proctoscope. Proctoscopes are hollow and have a small light at the end that allows the rectum to be inspected.

Transanal endoscopic microsurgery (TEM)

This type of transanal surgery removes tumors in the middle or upper rectum. General anesthesia with a nerve block is used. Based on the tumor location, you may lie on your stomach, back, or side.

A scope is inserted into the rectum. The scope has a light, camera, air ports, and an open channel. Air is pumped into the rectum to expand it. The light and camera allow the surgeon to see the tumor. The tumor is then

removed with small tools inserted through the open channel.

Transabdominal surgery

Transabdominal surgery involves cutting into the abdomen to reach and remove the cancerous tissue. The rectal tumor, surrounding tissue, and nearby lymph nodes are removed. All of the removed tissue is tested by a pathologist. The results of testing are used to determine the cancer stage.

Transabdominal surgery for rectal cancer involves total mesorectal excision (TME). The mesorectum is the fatty tissue surrounding the rectum that contains blood vessels and lymph nodes. A total mesorectal excision removes the mesorectum in one piece. Nerves are not removed.

An anastomosis is a type of surgery that connects two parts of the bowel. After transabdominal surgery for rectal cancer, the colon is often attached directly to the anus. This is called a coloanal anastomosis. It preserves the possibility of near-normal bowel movements.

If the colon cannot be connected to the anus, a colostomy is made. A colostomy connects a part of the colon to the outside of the abdomen. This creates an opening, called a stoma, on the surface of the abdomen. Stool exits the body through the stoma and goes into a bag attached to the skin. A colostomy may only be needed temporarily to allow the rectum to heal before an anastomosis. In some cases, it is necessary to surgically remove the anus. In this case, a colostomy is permanent. Colostomy is also known as diversion because it diverts (redirects) the flow of stool.


There is more than one type of transabdominal surgery. The method used depends on the location and extent of the cancer. At least 12 lymph nodes should be removed during all types of transabdominal surgery. Types of transabdominal surgery are described next.

Low anterior resection

A low anterior resection (LAR) is used for tumors in the mid to upper rectum. In addition to the cancerous area of the rectum, part or all of the sigmoid colon is removed. The sigmoid colon is the section of colon closest to the rectum. When possible, the colon is connected to the remaining rectum. This is called a colorectal anastomosis.

Low anterior resection (LAR)

LAR is the type of surgery used for tumors in the mid to upper rectum. The cancerous area of the rectum and part or all of the sigmoid colon is removed. When possible, the colon is connected to the remaining rectum.



© 2021 Terese Winslow LLC
U.S. Govt. has certain rights

Abdominoperineal resection

Abdominoperineal resection (APR) is used for tumors in the lower rectum. These tumors may have grown into the anus or nearby muscle (levator ani). An APR requires a second cut into the skin between the anus and genitals. This area is called the perineum.

APR typically involves removing the area where the rectum and the colon meet, the rectum, the anus, and other tissue. In some cases, the levator muscles are also removed. The outer ring of muscle in the anus may be spared. A permanent colostomy, described on the previous page, is needed.

Minimally invasive surgery


Instead of open surgery, a minimally invasive method may be an option. This method involves making a few small cuts into the abdominal wall, and possibly a cut between the legs. Thin tools are inserted into the cuts that allow the surgeon to see and remove tissue. Minimally invasive surgery should only be carried out by a surgeon experienced in this method. Also, this surgery should only be done on tumors that are not likely to return after treatment. Minimally invasive surgery is also known as laparoscopic surgery.

Side effects of surgery

Surgery causes pain, swelling, and scars. Pain and swelling often fade away in the weeks following surgery. Scars from surgery do not

Abdominoperineal resection (APR)

APR is used for tumors in the lower rectum that may have grown into the anus or nearby muscle. It involves removing the rectum and anus and creating a permanent colostomy for stool to leave the body.



© 2005 Terese Winslow
U.S. Govt. has certain rights

disappear completely. As with any surgery, there is a chance of complications. These include major blood loss, infection, heart attack, and blood clots. There can also be injury to nearby organs. Your surgical team will design care to minimize these risks.

There are short- and long-term side effects specific to rectal surgery. In the days or weeks following surgery, stool may leak out where the bowel was reconnected (anastomotic leak). This can cause pain, fever, and life-threatening infection. Your urine stream may be delayed during healing. If nerves or other structures are cut, bladder and sexual functioning may be impaired.

It is common for scar tissue to form after abdominal surgery. In some cases, however, there is so much scar tissue that the bowel becomes obstructed (blocked). In rare cases, the bowel may become tightly wrapped around an area of scar tissue. This is an emergency that requires hospitalization for bowel rest and possibly surgery.

A possible long-term effect of rectal surgery is hernia. Hernia refers to organs pushing through tissues or muscles weakened by surgery.

Not all side effects of surgery are listed here. Ask your treatment team for a complete list of common and rare side effects.

Systemic therapy

Systemic therapy is the use of medicine to kill cancer cells. The medicine(s) travel in the bloodstream to reach cells throughout the body. Systemic therapy can kill healthy cells in addition to cancer cells. The damage to healthy cells causes potentially harsh side effects, such as hair loss, cracked skin, and mouth sores. Most commonly, systemic therapy is given intravenously. This means the medicine is slowly infused into the bloodstream through a vein.

Types of systemic therapy include chemotherapy, targeted therapy, and immunotherapy. Unlike chemotherapy, targeted therapy and immunotherapy are most effective at treating cancers with specific features, called biomarkers. These newer types of systemic therapy may be treatment options for patients with advanced rectal cancer.

Systemic therapies are often combined to treat cancer. For example, several chemotherapy drugs may be given together, or a chemotherapy drug may be given with a targeted therapy. Combinations of systemic therapies are called regimens.

If systemic therapy is planned, the regimen(s) given depends (in part) on:

- Whether the cancer has metastasized (spread to areas outside the rectum)
- The results of tumor biomarker testing (see page 22 for more information)
- Your general health

Ask your treatment team for a full list of common and rare side effects of each systemic

therapy you are receiving. More information on the main types of systemic therapy is provided below.

Chemotherapy

Chemotherapy is the most commonly used type of systemic therapy for rectal cancer. It is given in cycles of treatment days followed by days of rest. This allows your body to recover between cycles. Cycles vary in length depending on which drugs are used. Chemotherapy regimens often used to treat rectal cancer are listed in [Guide 1](#).

The side effects of chemotherapy depend on many things (drug type, dosage, length of treatment) and are different for everyone. Common side effects include nausea, loss of appetite, diarrhea, hair loss, and mouth sores.

Some regimens are considered “intensive.” This means they may be harsh on the body. FOLFOX, CAPEOX, FOLFIRI, and FOLFIRINOX are intensive regimens. Any chemotherapy regimen that has “OX” in the name means the regimen includes oxaliplatin. Oxaliplatin can cause nerve damage (called neuropathy) to your fingers and toes. Symptoms include numbness, cramping, tingling, or pain in these areas.

Any chemotherapy regimen that has “IRI” in the name means it contains irinotecan. Irinotecan tends to cause abdominal cramping, nausea, diarrhea, and hair loss. It does not have the effects on nerves seen with oxaliplatin.

If regimens containing oxaliplatin and/or irinotecan are expected to be too harsh, your doctor may recommend 5-FU/leucovorin or capecitabine alone. Capecitabine is taken by

mouth. However, these regimens can also cause harsh side effects. Capecitabine can cause hand-foot syndrome. Symptoms include redness, swelling, and pain on the palms of the hands, bottoms of the feet, or both. Sometimes blisters appear. Your dose of capecitabine may be changed at the first sign of hand-foot syndrome.

Guide 1 Combination chemotherapy regimens

FOLFOX	FOL = Leucovorin calcium F = Fluorouracil OX = Oxaliplatin
CAPEOX	CAPE = Capecitabine OX = Oxaliplatin
FOLFIRI	FOL = Leucovorin calcium F = Fluorouracil IRI = Irinotecan
FOLFIRINOX	FOL = Leucovorin calcium F = Fluorouracil IRI = Irinotecan OX = Oxaliplatin
5-FU/LV	FU = Fluorouracil LV = Leucovorin calcium

Targeted therapy

Targeted therapy is treatment with drugs that target a specific or unique feature of cancer cells. Targeted therapies can work in one or more ways. They can treat rectal cancer by:

- Targeting and attacking specific receptors found on cancer cells
- Stopping overactive proteins inside the cancer cell from sending growth signals
- Stopping the growth of new blood vessels into rectal tumors, “starving” them

A targeted therapy known as a biologic may be added to chemotherapy to treat rectal cancer.

Immunotherapy

The immune system is your body’s natural defense against infection and disease. Immunotherapy increases the activity of parts of your immune system. This helps your body find and destroy cancer cells. Drugs called immune checkpoint inhibitors are immunotherapies used to treat rectal cancers that have certain biomarkers. They are not helpful for everyone.

Your immune system has important white blood cells called T cells. T cells’ main job is to attack harmful things in your body, like bacteria, viruses, and cancer. They do this with the help of certain proteins on their surface. When T-cell proteins “meet” certain proteins on cancer cells, it is called an immune checkpoint. The T cell is “told” to leave the cancer cell alone instead of attacking it. Checkpoint inhibitors can stop the T-cell protein from meeting the cancer cell protein. This means that the T cells will do their job and attack the cancer cells.

Checkpoint inhibitors currently used to treat some rectal cancers include pembrolizumab (Keytruda), nivolumab (Opdivo), and dostarlimab-gxly (Jemperli). Nivolumab may be given with another immunotherapy drug called ipilimumab (Yervoy).

For information on the side effects of immune checkpoint inhibitors, see the *NCCN Guidelines for Patients: Immunotherapy Side Effects: Immune Checkpoint Inhibitors* at [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines).



Radiation therapy

Radiation therapy uses high-energy rays to kill cancer cells.

External beam radiation therapy (EBRT)

EBRT is the type of radiation used most often to treat rectal cancer. This method delivers radiation from outside the body using a large machine. The radiation passes through skin and other tissue to reach the tumor. The radiation beams are shaped to the cancer site. This helps minimize damage to healthy tissue.

Types of EBRT include three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic body radiation therapy (SBRT). The type used depends on the location and size of the tumor(s) and other factors. SBRT is a highly specialized technique that may be used to treat metastatic rectal

cancer. See page 36 for more information on SBRT.

Long-course chemoradiation

External radiation therapy is often used with chemotherapy to treat rectal cancer. This is known as long-course chemoradiation. Radiation therapy is given in 25 to 28 treatment sessions, called fractions. Chemotherapy is given during the same period. When given with radiation, chemotherapy can make it easier for radiation to kill cancer cells. This is called radiosensitizing chemotherapy.

Short-course radiation therapy

Another method of radiation treatment for rectal cancer is short-course radiation therapy. This method delivers a higher dose of radiation over a much shorter time period, typically in 5 treatment sessions. Chemotherapy is not given.

External beam radiation therapy (EBRT)

A large machine aims radiation at the tumor, passing through skin and other tissue to reach it.



If external radiation is planned

A planning session, called simulation, is needed before treatment begins. After being guided into the treatment position, pictures of the cancer sites are made with an imaging test. Using the pictures, the radiation team plans the radiation dose and number of treatments.

During treatment, you will lie on a table as you did for simulation. Devices may be used to keep you from moving, with you sometimes lying on your back or on your stomach. This helps to target the tumor. Radiation beams are aimed with help from ink marks on your skin called tattoos, or marker seeds placed in the tumor.

You will be alone in the treatment room. A technician will operate the machine from a nearby room. You will be able to hear and speak with the technician at all times. As treatment is given, you may hear noises. You will not see, hear, or feel the radiation. One session can take less than 10 minutes. Sessions may take longer if imaging to verify the position is done before each treatment. Imaging before treatment is called image-guided radiation therapy (IGRT). The imaging in this case checks the position of the cancer and the accuracy of the setup, but does not tell the physician about the response of the tumor itself.

Other types of radiation therapy

Radiation can also be aimed directly at the tumor site during surgery, after the tumor is removed. The goal is to destroy any cancer cells that may be left in the tissue that was connected to the tumor. This is known as intraoperative radiation therapy (IORT).

What are some side effects of radiation therapy?

- Feeling tired and worn out
- Hair loss in the treated area
- Changes to urination and bowel movements
- Diarrhea
- Nausea/vomiting
- Late side effects can include infertility, sexual problems, bowel problems, reduced bone density, and second cancers
- Vaginal dilators can help with sexual problems—see the Survivorship section of this guide for more information
- Not all side effects are listed here. Ask your treatment team for a full list.

Another type involves using a tube called a catheter with a radiation source at the tip to treat rectal tumors directly. This is known as endorectal brachytherapy.

Local therapies for metastases

Treatment options for metastatic rectal cancer may include local therapies. Local therapies are treatments that target the metastatic tumors directly. They may be used to treat rectal cancer that spreads to the liver, lungs, or other areas.

Several of the local therapies described next are performed by an interventional oncologist/radiologist. Interventional oncology/radiology is a medical specialty that uses imaging techniques to deliver minimally invasive cancer treatments. Computed tomography (CT), ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT are imaging techniques that may be used. The use of imaging during the procedure allows the doctor to precisely target the tumor(s). Interventional oncology/radiology treatments are also known as image-guided therapies.

Resection

Surgery, also called resection, is often the preferred way to remove rectal cancer that has spread to the liver or lungs. A liver resection removes the cancerous part of the liver. A lung resection removes the part of the lung(s) with cancer. Another name for surgery to remove a metastasis is metastasectomy.

If the metastatic tumors are small, image-guided ablation (described next), may be offered instead of surgery in some cases. It may have similar results, but with fewer complications and a shorter recovery time.

If resection is possible but is not expected to completely remove the metastases, combined

treatment with both surgery and ablation may be an option.

Resection may not be possible because you have risk factors or certain health conditions. In this case, ablation or other local therapies described below and on the next page may be an option for treating metastases. A team of experts can determine the best local therapy for your metastatic tumor(s).

Portal vein embolization

If your doctor thinks your liver will be too small after a liver resection, you may need to have it enlarged. This is done using a minimally invasive procedure called portal vein embolization (PVE). An interventional radiologist uses a catheter inserted into certain veins in the liver. This blocks the blood vessel to the liver tumor, causing the healthy part of the liver to grow larger.

Image-guided ablation

Image-guided ablation destroys small liver or lung tumors with little harm to nearby tissue. It is performed by either an interventional radiologist with dedicated needles through the skin and image guidance, or by a surgeon during open surgery. Ablation may be used by itself for small tumors that can be completely destroyed, or it may be used in addition to surgery. Ablation will only be used if all visible areas of cancer can be destroyed. In some cases, ablation can be done as an outpatient in the interventional radiology department in a single session.

Currently, the most commonly used ablative therapies are radiofrequency (RFA) and microwave ablation. These methods kill cancer cells using heat. The delivery of cold energy—called cryoablation—is also used, mostly for

lung tumors. Other less common ablative methods include irreversible electroporation (IRE), also known as “NanoKnife” and laser ablation.

All ablative therapies are delivered using a specialized needle called a “probe” or “electrode” placed directly into or next to the target tumor. All types of ablation kill cancer cells by delivering targeted energy into the tumor while sparing or minimizing damage to normal tissues.

Liver-directed therapies

If the cancer has spread only (or mainly) to the liver, treatment with intra-arterial liver-directed therapies may be an option. This type of local therapy will be considered for liver tumors that:

- Did not (or no longer) improve with chemotherapy, and
- Cannot be resected or ablated.

Intra-arterial therapies treat liver tumors with chemotherapy beads (chemoembolization) or radioactive spheres (radioembolization). If radiation spheres are used, it is known as selective internal radiation therapy (SIRT) or transarterial hepatic radioembolization (TARE). These procedures are performed by interventional oncologists/radiologists.

A catheter is inserted into an artery in your leg or wrist and guided to the liver tumor(s). Once in place, the spheres or beads are injected into the blood vessel leading to the tumor. The spheres or beads collect inside the tumor and deliver radiation or chemotherapy, causing the cancer cells to die. The chemotherapy beads can also work to stop the blood supply to the tumor and starve the tumor. The

chemotherapy or radiation further damage the cancer cells and cause the tumor to shrink. When embolization with chemotherapy is not an option, bland embolization with small beads may be used. This involves physically blocking the blood supply to the tumor.

Another intra-arterial liver-directed therapy is hepatic arterial infusion chemotherapy (HAIC). While chemotherapy is traditionally given intravenously to reach cells throughout the body, HAIC is given directly to the liver to treat metastases. HAIC is often given in addition to standard intravenous chemotherapy. Using a port or pump that is usually placed during surgery to remove liver tumors, the drugs are funneled directly into the artery leading to the liver. HAIC should only be performed by medical oncologists at treatment centers with extensive experience in this method.

SBRT

Stereotactic body radiation therapy (SBRT) is a highly specialized type of radiation therapy. In SBRT, treatment is typically delivered in 5 or fewer sessions, called fractions. High doses of radiation are delivered to a metastatic site or sites using very precise beams. The treatment setup for SBRT is often more complex than typical external radiation therapy because higher doses of radiation therapy are delivered. SBRT may be used to treat rectal cancer that has spread to the liver, lungs, or bone.

MRI-Linac

The MRI-Linac is a recent development in radiation therapy. This device combines magnetic resonance imaging (MRI) with a radiation machine called a linear accelerator (LINAC). It is used in very specific

circumstances, such as when giving SBRT. If the cancer spreads to an area where the tumor moves as a result of breathing, the MRI-Linac may be helpful. It can “track” and target the tumor in real time while you hold your breath at regular intervals during the treatment.

Clinical trials

A clinical trial is a type of medical research study. After being developed and tested in a laboratory, potential new ways of fighting cancer need to be studied in people. If found to be safe and effective in a clinical trial, a drug, device, or treatment approach may be approved by the U.S. Food and Drug Administration (FDA).

Everyone with cancer should carefully consider all of the treatment options available for their cancer type, including standard treatments and clinical trials. Talk to your doctor about whether a clinical trial may make sense for you.

Phases

Most cancer clinical trials focus on treatment. Treatment trials are done in phases.

- **Phase I trials** study the dose, safety, and side effects of an investigational drug or treatment approach. They also look for early signs that the drug or approach is helpful.
- **Phase II trials** study how well the drug or approach works against a specific type of cancer.
- **Phase III trials** test the drug or approach against a standard treatment. If the



Finding a clinical trial

In the United States

NCCN Cancer Centers
[NCCN.org/cancercenters](https://www.nccn.org/cancercenters)

The National Cancer Institute (NCI)
[cancer.gov/about-cancer/treatment/clinical-trials/search](https://www.cancer.gov/about-cancer/treatment/clinical-trials/search)

Worldwide

The U.S. National Library of Medicine (NLM)
clinicaltrials.gov/

**Need help finding a clinical trial?
 NCI’s Cancer Information Service (CIS)**

1.800.4.CANCER (1.800.422.6237)
[cancer.gov/contact](https://www.cancer.gov/contact)

results are good, it may be approved by the FDA.

- **Phase IV trials** study the long-term safety and benefit of an FDA-approved treatment.

Who can enroll?

Every clinical trial has rules for joining, called eligibility criteria. The rules may be about age, cancer type and stage, treatment history, or general health. These requirements ensure that participants are alike in specific ways and that the trial is as safe as possible for the participants.

Informed consent

Clinical trials are managed by a group of experts called a research team. The research team will review the study with you in detail, including its purpose and the risks and benefits of joining. All of this information is also provided in an informed consent form. Read the form carefully and ask questions before signing it. Take time to discuss with family, friends, or others you trust. Keep in mind that you can leave and seek treatment outside of the clinical trial at any time.

Start the conversation

Don't wait for your doctor to bring up clinical trials. Start the conversation and learn about all of your treatment options. If you find a study that you may be eligible for, ask your treatment team if you meet the requirements. If you have already started standard treatment you may not be eligible for certain clinical trials. Try not to be discouraged if you cannot join. New clinical trials are always becoming available.

Frequently asked questions

There are many myths and misconceptions surrounding clinical trials. The possible benefits and risks are not well understood by many with cancer.

Will I get a placebo?

Placebos (inactive versions of real medicines) are almost never used alone in cancer clinical trials. It is common to receive either a placebo with a standard treatment, or a new drug with a standard treatment. You will be informed, verbally and in writing, if a placebo is part of a clinical trial before you enroll.

Are clinical trials free?

There is no fee to enroll in a clinical trial. The study sponsor pays for research-related costs, including the study drug. You may, however, have costs indirectly related to the trial, such as the cost of transportation or child care due to extra appointments. During the trial, you will continue to receive standard cancer care. This care is billed to—and often covered by—insurance. You are responsible for copays and any costs for this care that are not covered by your insurance.

Key points

Surgery

- Transanal surgery may be an option for some very early rectal cancers. The rectal tumor is removed through the anus.
- Transabdominal surgery involves cutting into the abdominal wall. It is used for many rectal cancers. The tumor, surrounding tissue, and nearby lymph nodes are removed.

Systemic therapy and radiation therapy

- Chemotherapy, targeted therapy, and immunotherapy are types of systemic therapy.
- Chemotherapy is the most commonly used type of systemic therapy for rectal cancer.
- Radiation therapy uses high-energy rays to kill cancer cells. External beam radiation therapy (EBRT) is used most often to treat rectal cancer.
- Radiation therapy and chemotherapy may be used together to treat rectal cancer. This is known as chemoradiation.

Local therapies for metastases

- When possible, surgery (resection) is typically preferred for removing liver or lung metastases.
- Image-guided ablation destroys small liver or lung tumors with little harm to nearby tissue. It may be used with surgery or by itself for certain small tumors.
- Liver-directed therapies may be an option for liver tumors that did not (or no longer)

improve with chemotherapy and that cannot be resected or ablated.

- SBRT is a specialized type of radiation therapy that may be used to treat rectal cancer that has spread to the liver, lungs, or bone.

Clinical trials

- Clinical trials give people access to investigational treatments that may, in time, be approved by the U.S. FDA.



Being diagnosed with stage IV rectal cancer at age 36 was overwhelming. Fortunately, there are many fantastic online resources and support groups. It helped me to talk to other patients and know that I'm never alone.

– Peg

Rectal cancer survivor

4

Non-metastatic cancer

- 41 Cancerous polyps
- 43 If surgery is needed
- 46 Surveillance
- 48 Recurrence
- 49 Key points



This chapter is a treatment guide for rectal cancer that has not spread to areas far from the rectum.

Rectal cancer often forms in polyps on the lining of the rectum. It can also take the form of lesions on the inside of the rectum.

Cancerous polyps

A polyp is an overgrowth of cells on the inner lining of the rectal wall. The most common type is called an adenoma. Adenomas are considered pre-cancerous. While it may take many years, adenomas can become invasive rectal cancer. Cancer that forms in an adenoma is known as an adenocarcinoma.

The two main shapes of polyps are sessile and pedunculated. Pedunculated polyps are

shaped like mushrooms and stick out from the rectal wall. They have a stalk and round top. Sessile polyps are flatter and do not have a stalk.

If not found and removed early enough, cancer that starts in a polyp can grow into the rectal wall. This is referred to as a cancerous (malignant) polyp. Most polyps can be removed during a colonoscopy, using a minor surgical procedure called a polypectomy. In some cases, no further treatment is needed after a polypectomy.

In other cases, resection (surgical removal) of a bigger piece of the rectum is needed. This depends on the shape of the polyp (pedunculated or sessile), the results of the polypectomy, and the results of testing the removed tissue. Before deciding whether resection is needed after a polypectomy, your

Pedunculated polyp

Pedunculated polyps have a stalk and are mushroom-like in appearance. No further treatment is needed for a cancerous pedunculated polyp that was completely removed in one piece and found to be low risk based on testing.



doctor will review the results of testing with you and discuss your options.

Good polypectomy results

No further treatment is needed for a cancerous **pedunculated** polyp that was completely removed in one piece and found to be low risk based on testing.

Cancerous **sessile** polyps are more likely to return after polypectomy. These polyps often have other poor treatment outcomes. For this reason, surgery is a recommended treatment option for sessile polyps—even those with good results of polypectomy and testing. Observation is also an option. If surgery is planned for a sessile polyp, transanal surgery may be an option. Otherwise, transabdominal surgery is recommended. Depending on the type of surgery planned, see *After transanal surgery* (page 43) or *After transabdominal surgery* (page 44) for next steps.


Other polypectomy results

If the polyp is not removed in one piece, or if testing of the removed polyp finds high-risk features, surgery is needed. Transanal surgery may be an option for small tumors that have not invaded the muscle layer of the rectal wall. See *After transanal surgery* on the next page for information on next steps.

Rectal tumors that cannot be removed by transanal excision are removed by transabdominal resection. This type of surgery requires cutting into the abdomen to reach and remove the cancer. See *After transabdominal surgery* on page 44 for information on next steps.

Sessile polyp

Sessile polyps don't have a stalk and can be harder to spot than pedunculated polyps. Cancerous sessile polyps are more likely to return after polypectomy than pedunculated polyps. Surgery is an option for sessile polyps.



If surgery is needed

If cancer that formed in a polyp is not found early enough to be removed by polypectomy, surgery is needed. Surgery is also needed for rectal cancer that forms in lesions on the rectal wall.

The true extent of the cancer cannot be known until after surgery. It can be estimated, however, based on the results of certain tests. This is known as the clinical (pre-surgery) stage. The clinical stage is used to determine your treatment options.

Testing before treatment includes:

- Colonoscopy
- Biopsy
- Testing of removed tissue
- Mismatch repair (MMR) or microsatellite instability (MSI) testing
- Blood tests including complete blood count (CBC), chemistry profile, carcinoembryonic antigen (CEA) level
- Computed tomography (CT) of the chest
- CT or magnetic resonance imaging (MRI) of the abdomen
- MRI of the pelvis with rectal cancer staging technique
- Endoscopic rectal ultrasound (ERUS) and CT of the pelvis if you cannot have pelvic MRI
- Additional imaging tests as needed

More information on these tests can be found in *Part 2: Treatment planning*.

Early rectal cancer

If testing finds that the tumor has not grown beyond the second layer of the rectal wall (the submucosa), it is a T1 tumor. Transanal surgery may be an option. Other criteria must be met for transanal surgery to be considered. Otherwise, transabdominal surgery is recommended.

If testing finds that the tumor has invaded the muscle layer of the rectal wall but has not grown beyond it (a T2 tumor), transabdominal resection is recommended.

See *After transanal surgery* or *After transabdominal surgery* for next steps.

After transanal surgery

If the cancer is confirmed to be T1 (has not grown farther than the second layer of the rectum wall) and the tumor is considered low risk, no further treatment is needed.

If high-risk features are found, or if the tumor is T2, more treatment is needed. T2 tumors have invaded the muscle layer of the rectal wall. In this case, the preferred next treatment is transabdominal surgery. Another option is treatment with chemoradiation next. If surgery is planned, see *After transabdominal surgery* on the next page. If chemoradiation is planned, keep reading.

If there are no signs of cancer after chemoradiation, there are two possibilities. You may have chemotherapy with FOLFOX or CAPEOX to kill any cancer cells that remain in the body. Or, a watch-and-wait approach may be taken. This approach is only an option for highly selected patients who agree to careful follow-up programs with endoscopic exam and

MRI of the pelvis with a rectal cancer staging technique.

If there are signs of cancer after chemoradiation, transabdominal resection is recommended. Chemotherapy with FOLFOX or CAPEOX may be given after surgery to kill any cancer cells that remain in the body.

See *Surveillance* on page 47 for next steps.

After transabdominal surgery

The tissue and lymph nodes removed during transabdominal surgery are sent to a pathologist to be examined. The pathologist assesses how far the cancer has grown within the rectal wall and assigns the cancer a stage. The stage is used to determine whether more treatment is needed.

If the cancer has not spread beyond the muscle layer of the rectum wall (either a T1 or a T2 tumor), the cancer is stage I. No further treatment is needed.

If the cancer is stage II or III, more treatment is almost always needed. Stage II rectal cancer has spread beyond the rectum into nearby areas, but not to nearby lymph nodes. Stage III rectal cancers have spread to nearby lymph nodes. Observation may be an option after surgery for some very low-risk stage II cancers.

Next treatments may include:

- Chemoradiation followed by chemotherapy
- Chemotherapy followed by chemoradiation
- Chemotherapy alone

Chemotherapy medicines recommended for use with radiation include 5-fluorouracil (5-FU) and capecitabine. If you cannot have either of these, a third option is 5-FU/leucovorin given in single, large doses. When chemotherapy is given by itself (not as part of chemoradiation), either FOLFOX or CAPEOX is recommended.

See *Surveillance* on page 47 for next steps.



Let us know what you think!

Please take a moment to complete an online survey about the NCCN Guidelines for Patients.

[NCCN.org/patients/response](https://www.nccn.org/patients/response)

Locally advanced rectal cancer

Testing before treatment may find that the cancer is locally advanced. This means that the cancer:

- Has spread to nearby lymph nodes
- OR
- Has grown all the way through the rectal wall (a T3 or T4 tumor)
- OR
- Cannot be removed with surgery, or for which surgery is otherwise not an option

Unlike early rectal cancers, most locally advanced cancers are treated first with 12 to 16 weeks of chemotherapy **and** either long-course chemoradiation or short-course radiation therapy. **This preferred treatment**

approach is known as total neoadjuvant therapy (TNT). Chemotherapy may be given first, followed by chemoradiation or short-course radiation. Or, chemoradiation or short-course radiation may be given first, followed by chemotherapy. Your treatment team will determine the best treatment order for you. When chemotherapy is given by itself (not as part of chemoradiation), either FOLFOX or CAPEOX is usually given. FOLFIRINOX may be used in some cases. If total neoadjuvant therapy works well, surgery may be an option.

Sometimes, only long-course chemoradiation or short-course radiation therapy is given first, followed by surgery if possible. This approach is known as simply neoadjuvant therapy. In this case, chemotherapy with FOLFOX or CAPEOX is given after surgery and is called adjuvant therapy.

Long-course chemoradiation



- 25 to 28 radiation treatment sessions (Monday through Friday)
- Chemotherapy is given during the same time period
- Either 5-fluorouracil or capecitabine is usually given for chemotherapy

Short-course radiation therapy



- High-dose radiation is given over a short time period
- Typically only 5 treatment sessions are needed

For many years, long-course chemoradiation was the standard approach for treating locally advanced rectal cancer. Short-course radiation therapy is another option found to have similar outcomes.

After initial treatment

After treatment, imaging tests will be ordered to see if surgery (transabdominal resection) is an option. This is called restaging. If surgery is possible, it is recommended for most people. Chemotherapy with FOLFOX or CAPEOX may be given after surgery.

Chemotherapy and radiation therapy may work so well that no cancer can be detected in the body. If this happens, some research suggests that having surgery does not always lead to better treatment outcomes. You may be given the option to “watch and wait” instead of having surgery. This is only an option for carefully selected patients who agree to close surveillance programs. Surveillance involves digital rectal exams, proctoscopy, and MRI of the pelvis with a rectal cancer staging technique. The benefits and risks of taking a watch-and-wait approach versus having surgery are not fully known. The decision to pursue surgery (or not) should be one that you and your doctor make together after careful consideration.

If surgery is still not an option after chemotherapy and/or radiation, treatment with systemic therapy is recommended. Your doctor will consider the following in order to select an appropriate regimen for you:

- Chemotherapy medicines you’ve already received
- Whether the tumor has any biomarkers (see page 22 for information on biomarkers)
- How well you are expected to tolerate certain systemic therapies

Surveillance

Follow-up testing is started when there are no signs of cancer after treatment. It is helpful for finding new cancer growth early.

Stage I

Surveillance for stage I rectal cancer depends on the type(s) of surgery received. If you had transanal surgery only, regular proctoscopies and colonoscopies are needed. If transabdominal surgery with full surgical staging was performed, only colonoscopies are needed. See [Guide 2](#) on the next page.

If you don’t have any symptoms, other testing is not needed on a regular basis. Your doctor may order imaging tests if they suspect the cancer may have come back or spread.

Stages II and III

In addition to colonoscopy, surveillance for stage II and III rectal cancer includes physical exams, CEA blood tests, and CT scans. Rising CEA levels may be a sign that rectal cancer has returned. CT scans can find metastases, should any develop. The recommended schedule for surveillance testing is shown in [Guide 3](#) on the next page.

In addition to surveillance testing, a range of other care is important for cancer survivors. See *Part 6: Survivorship* section of this guide for more information.

Guide 2 Surveillance for stage I rectal cancer

<p>You had transanal surgery only</p>	<ul style="list-style-type: none"> • Proctoscopy every 3 to 6 months for the first 2 years, then every 6 months for another 3 years • Colonoscopy 1 year after surgery <ul style="list-style-type: none"> • If an advanced adenoma is not found, repeat in 3 years, then every 5 years • If an advanced adenoma is found, repeat in 1 year
<p>You had transabdominal resection</p>	<p>Colonoscopy 1 year after surgery</p> <ul style="list-style-type: none"> • If an advanced adenoma is not found, repeat in 3 years, then every 5 years • If an advanced adenoma is found, repeat in 1 year

Guide 3 Surveillance for stage II and stage III rectal cancer

<p>Medical history and physical exam</p>	<p>Every 3–6 months for first 2 years, then every 6 months for 3 more years</p>
<p>CEA blood test</p>	<p>Every 3–6 months for first 2 years, then every 6 months for 3 more years</p>
<p>CT of chest, abdomen, and pelvis</p>	<p>Every 6–12 months for 5 years</p>
<p>Colonoscopy</p>	<p>You did not have a total colonoscopy at diagnosis: Colonoscopy recommended 3 to 6 months after surgery</p> <p>You had a total colonoscopy at diagnosis: Colonoscopy recommended 1 year after surgery</p> <ul style="list-style-type: none"> • If no advanced adenoma found, repeat in 3 years, then every 5 years • If advanced adenoma found, repeat in 1 year

Recurrence

Cancer that returns to the rectum or to nearby areas in the pelvis is called a local recurrence. Treatment options depend on whether the cancer is (or may become) resectable and whether you have had previous radiation to your pelvis.

If the cancer is small enough, your first treatment may be surgery. After surgery, chemoradiation is given to kill any remaining cancer cells. Otherwise, chemotherapy and either long-course chemoradiation or short-course radiation therapy is given before surgery.

If surgery is not possible, you may have treatment with systemic therapy, chemoradiation, or short-course radiation. If systemic therapy is planned, your doctor will consider the following in order to select an appropriate regimen for you:

- Chemotherapy medicines you've already received
- Whether the tumor has any of the biomarkers (see *Part 2: Treatment planning* for information on biomarkers)
- How well you are expected to tolerate certain systemic therapies

If cancer returns to areas far from the rectum, it is called a distant recurrence. See *Part 5: Metastatic cancer* for information.



share with us.

Take our [survey](#)

**And help make the
NCCN Guidelines for Patients
better for everyone!**

[NCCN.org/patients/comments](https://www.nccn.org/patients/comments)

Key points

Cancerous polyps

- No further treatment is needed for a cancerous pedunculated polyp that was removed in one piece and found to be low risk based on testing.
- Surgery is an option for cancerous sessile polyps, which are more likely to return after polypectomy than pedunculated polyps.

Early rectal cancer

- Transanal surgery may be an option for some very early rectal cancers that have not grown beyond the second layer of the rectum wall.
- Transabdominal surgery is recommended for early rectal cancers that do not meet the criteria for transanal surgery.
- No further treatment is needed for cancers found to be stage I after transabdominal surgery.
- More treatment is almost always needed for cancers found to be stage II or III after transabdominal surgery. Treatment after surgery often includes chemotherapy and chemoradiation.

Locally advanced rectal cancer

- The term “locally advanced” is used to describe rectal cancer that has grown through the rectum wall and into nearby areas, or that has spread to nearby lymph nodes.
- Most locally advanced cancers are treated with chemotherapy and either

long-course chemoradiation or short-course radiation therapy. This is known as total neoadjuvant therapy. If these treatments work well, surgery may be an option.

Surveillance

- Colonoscopies are used to monitor for the return of all stage I rectal cancers. If transanal surgery was the only type of surgery performed, proctoscopies are also needed for the first 5 years after surgery.
- Surveillance for stage II and III rectal cancer includes physical exams, CEA blood tests, colonoscopies, and CT scans.

5

Metastatic cancer

- 51 Stage IV rectal cancer
- 54 Surveillance
- 55 Metastasis at recurrence
- 56 Key points



Rectal cancer spreads most often to the liver, sometimes to the lungs, and less often to the abdomen or other areas. Cancer may have already spread by the time it is diagnosed. This is stage IV rectal cancer. More commonly, metastases develop after treatment for non-metastatic rectal cancer.

About half of people with rectal cancer will develop metastases. Most will be liver metastases that cannot be removed with surgery. This section discusses both stage IV rectal cancer and metastasis after treatment. Although both are considered metastatic cancer, there are some differences in treatment.

Stage IV rectal cancer

If cancer was found in areas far from the rectum when you were first diagnosed, the cancer is stage IV. Testing for suspected (or known) stage IV rectal cancer includes:

- Colonoscopy
- Proctoscopy (as needed)
- CT scan of the chest
- CT or MRI of the abdomen
- MRI of the pelvis with rectal cancer staging technique (with or without contrast)
- Complete blood count (CBC) and chemistry profile
- Carcinoembryonic antigen (CEA) level
- Biopsy if needed
- Biomarker testing

The presence of biomarkers helps guide treatment for metastatic rectal cancer. Everyone with metastatic rectal cancer should have their tumor tested for the biomarkers listed below.

- *RAS* and *BRAF* mutations
- HER2 amplification (not needed if there is a *RAS* or *BRAF* mutation)
- Mismatch repair deficiency (dMMR)/ microsatellite instability-high (MSI-H) (if not already performed)

Testing for these biomarkers may be performed individually, or as part of a larger panel (group). Testing for many biomarkers at one time is called next-generation sequencing (NGS). NGS can find other, rare gene mutations for which targeted treatments may be available.

More information on these tests can be found in *Part 2: Treatment planning*.

Cancer in the liver and/or lungs

When possible, surgery (resection) is the preferred way to treat rectal cancer that has spread to the liver or lungs. In some patients with small tumors, image-guided ablation may be offered instead of surgery. It may have similar results but fewer complications.

When surgery is not expected to completely remove the metastases, combination treatment with ablation may be an option. For patients unable to undergo resection due to other health conditions, treatment with ablation or other local therapies may be possible. See page 35 for information on local therapies for metastases.

To determine if surgery or treatment with local therapies is an option, your case should be evaluated by a multidisciplinary team of experts that includes a surgeon experienced in removing liver and lung tumors and an interventional oncologist/radiologist with expertise in image-guided therapies such as ablation or hepatic arterial liver-directed therapies. Additional imaging tests such as a PET/CT scan or an MRI of the liver may be ordered to help determine if surgery is an option. If you are a candidate for surgery first, see “Upfront surgery is possible” on the next page.

The primary treatment for stage IV rectal cancer that cannot be removed with surgery and/or ablation is systemic therapy. Systemic therapy given first is called first-line therapy.

If one regimen does not work or stops working, there are other options that may work for you. These are called second- and third-line regimens. Some of the options depend on what treatment you’ve already had.

First-line systemic therapy

One of the following chemotherapy regimens is usually given first:

- FOLFIRI
- FOLFOX
- CAPEOX
- FOLFIRINOX

A targeted therapy known as a biologic may also be included in the chemotherapy regimen. Biologics include:

- Bevacizumab (Avastin)

- Panitumumab (Vectibix)
- Cetuximab (Erbix)

Panitumumab and cetuximab are only used for rectal tumors that have normal *KRAS/NRAS* and *BRAF* genes.

For MSI-H/dMMR tumors, immunotherapy may be an option. There is not as much research available on this option. Talk to your doctor about immunotherapy versus chemotherapy if your cancer is MSI-H/dMMR. Currently recommended immunotherapies include pembrolizumab (Keytruda) and nivolumab (Opdivo). Nivolumab may be given with another immunotherapy called ipilimumab (Yervoy).

Although uncommon, systemic therapy may shrink the tumors enough to be removed with surgery. If this occurs, surgery is recommended. You may have short-course radiation therapy or chemoradiation before surgery. Although surgery is preferred to remove metastases, treatment with other local therapies such as ablation or SBRT is also an option.

If the cancer does not become resectable, systemic therapy is typically continued. The goal is to slow the growth and spread of the cancer. If there are a limited number of liver or lung tumors, treatment with local therapies may also be an option. If the rectal tumor grows during initial systemic therapy, you may first have chemoradiation or a short course of radiation to the rectal tumor before continuing systemic therapy.

Second-line therapy and beyond

The regimen you receive next may be different from what you had before. The choice of regimen will depend on prior systemic therapy received, whether the cancer has any biomarkers, and how well you are expected to tolerate certain systemic therapies.

Options for MSI-H or dMMR tumors may include:

- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo) with or without ipilimumab (Yervoy)
- Dostarlimab-gxly (Jemperli)

Options for HER2-positive rectal cancers include:

- Trastuzumab (Herceptin) with either pertuzumab (Perjeta) or lapatinib (Tykerb)
- Fam-trastuzumab deruxtecan-nxki (Enhertu)

If the cancer progresses again, third-line systemic therapy options may include:

- Chemotherapy with trifluridine and tipiracil (Lonsurf)
- Targeted therapy with regorafenib (Stivarga)

Lonsurf and Stivarga are tablets taken by mouth. The targeted therapy bevacizumab (Avastin) may be given in combination with Lonsurf.

See *Surveillance* on the following page for next steps.

Upfront surgery is possible

If all areas of cancer are resectable, surgery is recommended. Systemic therapy and either chemoradiation or short-course radiation therapy are given before surgery. The order in which these treatments are given can vary. Systemic therapy may be given first, followed by chemoradiation or short-course radiation therapy and then surgery. Or, either short-course radiation or chemoradiation may be given first, followed by systemic therapy and then surgery. Your treatment team will determine the optimal treatment order for you.

For systemic therapy, chemotherapy with FOLFOX, CAPEOX, 5-FU/leucovorin or capecitabine is recommended. For MSI-H/dMMR tumors, immunotherapy with pembrolizumab or nivolumab may be an option. Nivolumab may be given with another immunotherapy called ipilimumab. There is not as much research available on this option. Talk to your doctor about immunotherapy versus chemotherapy before surgery if your cancer is MSI-H/dMMR.

Surgery to remove the rectal tumor and the metastases may be done at the same time, or in separate surgeries. Although surgery is preferred to remove the metastases, treatment with local therapies such as ablation or SBRT may be appropriate if there is a limited number of small tumors.

Cancer in the abdomen

Some people with metastatic rectal cancer will also form tumors in the peritoneum. The peritoneum is the thin layer of tissue that lines the abdomen and covers most of the abdominal organs. The goal of care for rectal cancer that has spread to the abdomen is to relieve or prevent symptoms. The main

treatment is systemic therapy. The regimen you receive will depend on whether the tumor has any biomarkers (see page 22 for information on biomarkers) and how well you are expected to tolerate certain systemic therapies.

Tumors growing in or around the bowel can block the flow of stool. This is called a bowel obstruction. If the cancer is (or is expected to) block the bowel, you will first need care to unblock the bowel before starting systemic therapy. This can be done using one of several surgical techniques, or with a mesh metal tube called a stent.

Surveillance

Surveillance for stage IV rectal cancer includes colonoscopies, physical exams, CEA blood tests, and CT scans. Rising CEA levels may be a sign that rectal cancer has returned. CT scans can help find new metastases. The recommended schedule for surveillance testing is shown in [Guide 4](#).

In addition to surveillance testing, a range of other care is important for cancer survivors. See the *Survivorship* section of this guide on page 57 for more information.

Guide 4 Surveillance for stage IV rectal cancer

Medical history and physical exam	Every 3–6 months for first 2 years, then every 6 months for 3 more years
CEA blood test	Every 3–6 months for first 2 years, then every 6 months for 3 more years
CT of chest, abdomen, and pelvis	Every 3–6 months for first 2 years, then every 6–12 months for 3 more years
Colonoscopy	<p>You did not have a total colonoscopy at diagnosis: Colonoscopy recommended 3 to 6 months after surgery</p> <p>You had a total colonoscopy at diagnosis: Colonoscopy recommended 1 year after surgery</p> <ul style="list-style-type: none"> • If no advanced adenoma, repeat in 3 years, then every 5 years • If advanced adenoma, repeat in 1 year

Metastasis at recurrence

If cancer returns after initial treatment of localized rectal cancer and is found in distant areas, such as the liver or lungs, it is called a distant recurrence. Treatment with surgery and/or local therapies is recommended if all of the tumors can be totally removed. However, this is not often possible. You may have a PET/CT scan to help determine whether surgery is possible. If it is, chemotherapy may be given before surgery, after surgery, or both.

Most distant recurrences are treated with systemic therapy. It is likely that you received oxaliplatin-based chemotherapy as part of initial treatment. CAPEOX and FOLFOX are oxaliplatin-based regimens. Oxaliplatin can cause serious nerve damage and should not be given too often. For this reason, if you've had recent treatment with FOLFOX

or CAPEOX, you should not have more chemotherapy that includes oxaliplatin. The recommended options for systemic therapy are shown in [Guide 5](#).

While uncommon, systemic therapy may shrink the tumors enough for them to be removed with surgery and/or local therapies. If not, systemic therapy is typically continued. The goal is to slow the growth and spread of the cancer. Treatment with local therapies may also be an option. The choice of systemic therapy regimen will depend on prior systemic therapy received, whether the cancer has any biomarkers, and how well you are expected to tolerate certain systemic therapies.

Guide 5

Systemic therapy for distant recurrence – recent treatment with FOLFOX or CAPEOX

Type of systemic therapy	Regimens
Chemotherapy	<ul style="list-style-type: none"> • FOLFIRI with or without a biologic • Irinotecan with or without a biologic Biologics include bevacizumab, ziv-aflibercept, ramucirumab, cetuximab,* and panitumumab* *For cancers without <i>RAS</i> or <i>BRAF</i> mutations
Immunotherapy (dMMR/MSI-H tumors only)	<ul style="list-style-type: none"> • Pembrolizumab (Keytruda) • Nivolumab (Opdivo) with or without ipilimumab (Yervoy)
Targeted therapy (<i>BRAF</i> V600E positive tumors)	<ul style="list-style-type: none"> • Encorafenib (Braftovi) + cetuximab (Erbix) or panitumumab (Vectibix)

Key points

- Metastasis refers to the spread of cancer cells to distant areas.
- If metastases are present at the time of diagnosis, it is stage IV rectal cancer.
- Most commonly, metastases develop after treatment for non-metastatic rectal cancer. This is known as a distant recurrence.
- Local therapies may be used to treat some metastatic rectal cancers. Local therapies include image-guided ablation, intra-arterial liver-directed therapies, and SBRT.
- When possible, surgery and/or ablation is preferred to treat rectal cancer that has spread to the liver or lungs. However, most liver and lung metastases cannot be removed using surgery and/or local therapies.
- Metastatic rectal cancer that cannot be completely removed with surgery and/or local therapies is treated with systemic therapy.
- Supportive (also called palliative) care is available for everyone with cancer. It isn't meant to treat the cancer, but rather to help with symptoms and make you more comfortable.



We want your feedback!

Our goal is to provide helpful and easy-to-understand information on cancer.

Take our survey to let us know what we got right and what we could do better:

[NCCN.org/patients/feedback](https://www.nccn.org/patients/feedback)

6

Survivorship

58 Your primary care doctor

59 Help with side effects

61 Healthy habits

62 More information

62 Key points



Survivorship focuses on the physical, emotional, and financial issues unique to cancer survivors. Managing the long-term side effects of cancer and its treatment, staying connected with your primary care doctor, and living a healthy lifestyle are important parts of survivorship.

Rectal cancer survivors may experience both short- and long-term health effects of cancer and its treatment. The effects depend on the treatment(s) received. Surgery, systemic therapy, and radiation therapy all have unique potential side effects.

Staying connected with your primary care doctor and practicing healthy habits can help prevent or offset these effects. It can also help lower the risk of getting other types of cancer.

Cancer survivors face a unique financial burden. Paying for doctor visits, tests, and treatments can become unmanageable, especially for those with little or no health insurance. You may also have costs not directly related to treatment, such as travel expenses and the cost of childcare or missed work.

The term financial toxicity is used to describe the problems patients face related to the cost of medical care. Financial toxicity can affect your quality of life and access to needed health care. If you need help paying for your cancer care, financial assistance may be available. Talk with a patient navigator, your treatment team's social worker, and your hospital's financial services department. Several of the resources listed on page 68 contain helpful information on paying for cancer care.

Your primary care doctor

After finishing cancer treatment, your primary care doctor will play an important role in your care. Your oncologist (cancer doctor) and primary care physician (PCP) should work together to make sure you get the follow-up care you need. Your oncologist will develop a survivorship care plan that includes:

- A summary of your cancer treatment history
- A description of possible late- and long-term side effects
- Recommendations for monitoring for the return of cancer
- Information on when your care will be transferred to your PCP
- Clear roles and responsibilities for both your cancer doctor and your PCP
- Recommendations on your overall health and well-being



When you are deciding on your treatment options remember that even though some decisions need to be made fast, don't rush. Think through your options and get second, or even third opinions. Have people you can trust to talk through your options so you feel comfortable in your decision.

– Cari

Rectal cancer survivor

Help with side effects

Bowel changes

Surgery that involves removing all or part of the rectum can result in changes to bowel function. This type of surgery is called a low anterior resection (LAR). These changes can include:

- Overall increase in bowel movements
- Urgent need to pass stool
- Having many (possibly watery) bowel movements over the course of a few hours (stool clustering)
- Irregular and unpredictable bowel movements
- Inability to control bowel movements (fecal incontinence)
- Increase in gas (flatulence)

Together these symptoms are referred to as low anterior resection syndrome (LARS). There are ways to control or lessen these symptoms. The over-the-counter anti-diarrheal medicine loperamide (Imodium) can help with stool clustering and incontinence.

Exercises that strengthen the muscles in the pelvic floor can help with urgency and stool incontinence. Changes to diet can also help with these LARS symptoms. Eat foods high in insoluble (not soluble) fiber and use fiber supplements. Psyllium-based products (Metamucil, for example) may help slow and thicken the stool. Ask your treatment team for a list of foods that may help or worsen bowel changes after low anterior resection. Many people find that wearing protective undergarments provides peace of mind.

Nerve damage

The chemotherapy drug oxaliplatin can cause nerve damage to fingers and toes. Symptoms include numbness, cramping, tingling, or pain in these areas. Acupuncture and/or heat may help. If you have painful nerve damage, a drug called duloxetine (Cymbalta) may help. If the pain is persistent, talk to your doctor about seeing a pain management specialist.

Ostomy care

If you have an ostomy, you may want to join an ostomy support group. Another option is to see a health care provider that specializes in ostomy care, such as an ostomy nurse. People with ostomies can still live very active lifestyles. However, it's a good idea to talk to an ostomy professional before doing any intense physical activity.

Sexual health

Many people experience sexual side effects after chemotherapy and radiation. For those with a penis, this could mean difficulty getting an erection. Those with a vagina may experience vaginal dryness and pain during sex.

Vaginal stenosis

Radiation therapy to the pelvis can cause the vagina to become shorter and more narrow. This is called vaginal stenosis. Vaginal stenosis can make it uncomfortable or even painful to have sex, or to have vaginal examinations by a doctor. Vaginal dilator therapy can help. A vaginal dilator is a device used to gradually stretch or widen the vagina. Vaginal dilators are not one-size-fits-all. Different sizes are available, as are kits containing different size devices. The size of the dilator can be increased over time as the vagina lengthens.

and widens. Use of a vaginal dilator can begin as soon as you are healed after treatment.

Hormone replacement therapy (HRT)

The ovaries make hormones needed for menstruation and natural pregnancy. Radiation damages the ovaries, causing hormone levels to drop. This is known as premature ovarian insufficiency (POI) or radiation-induced premature menopause. The drop in estrogen can cause symptoms of menopause, including:

- Hot flashes
- Sleeping problems
- Night sweats
- Weight gain
- Changes in mood
- Vaginal dryness

HRT may help. One option is systemic combination HRT. Both estrogen and progesterone are given, often as a pill taken by mouth or a patch placed on the skin. The hormones travel throughout the body in the bloodstream. Progesterone is included because giving estrogen by itself can increase the risk of uterine cancer in those with a uterus.

Another option for HRT is vaginal estrogen cream or tablets. This type may be the best option for symptoms that mainly affect the vagina, such as dryness.

Bone loss

Pelvic radiation treatment can weaken bones in the pelvis. In those with ovaries, the loss of estrogen after pelvic radiation can weaken bones throughout the body. This can lead to fractures (breaks). Your doctor may want to start monitoring the density of your bones.



Complementary and alternative therapies

Complementary and alternative therapies may help with side effects and improve comfort and well-being during and after cancer treatment. Some of these practices and products include:

Acupuncture
 Dietary supplements
 Eastern medicine
 Medical marijuana
 Herbal teas and preparations
 Homeopathy
 Hypnosis
 Meditation
 Reiki
 Yoga
 Massage therapy

If you have questions or are curious about complementary therapies, talk to your treatment team. Many cancer centers have integrative oncology programs. Integrative oncology is an approach to cancer care that combines conventional (standard) cancer treatment with complementary and alternative therapies.

Healthy habits

Monitoring for the return of cancer is important. But it is also important to keep up with other aspects of your health. Steps you can take to help prevent other health issues and to improve your quality of life are described next.

Cancer screening

Get screened for other types of cancer, such as breast, prostate, and skin cancer. Your primary care doctor can tell you the recommended screening tests based on your age and risk level.

Other health care

Get other recommended health care for your age, such as blood pressure screening, hepatitis C screening, and immunizations (like the flu shot).

Diet and exercise

Leading a healthy lifestyle includes maintaining a healthy body weight. Try to exercise at a moderate intensity for at least 150 minutes per

week. Talk to your doctor before starting a new exercise regimen.

Eat a healthy diet with lots of plant-based foods. A low glycemic load (GL) diet may help prevent the return of rectal cancer. Low GL foods cause a slower and smaller rise in blood sugar levels compared to other carbohydrate-containing foods. Talk to your doctor about a low glycemic load diet. Alcohol may increase the risk of certain cancers. Drink little to no alcohol.

Aspirin

Talk to your doctor about taking aspirin every day to help prevent the return of colorectal cancers.

Quit smoking

If you are a smoker, quit! Your doctor will be able to provide (or refer you for) counseling on how to stop smoking.

Experts recommend eating a healthy diet, especially one that includes a lot of plant-based foods (vegetables, fruits, and whole grains).



More information

For more information on cancer survivorship, the following are available at [NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines):

- *Survivorship Care for Healthy Living*
- *Survivorship Care for Cancer-Related Late and Long-Term Effects*



These resources address many topics relevant to cancer survivors, including:

- Anxiety, depression, and distress
- Cognitive dysfunction
- Fatigue
- Pain
- Sexual problems
- Sleep problems
- Healthy lifestyles
- Immunizations
- Employment, insurance, and disability concerns

Key points

- Survivorship focuses on the physical, emotional, and financial issues unique to cancer survivors.
- Your oncologist and primary care doctor should work together to make sure you get the follow-up care you need.
- The care recommended for you after cancer treatment should be detailed in a written survivorship care plan.
- Leading a healthy lifestyle after cancer means drinking little to no alcohol, eating a healthy diet, exercising, quitting smoking, and keeping up with other aspects of your health.
- If you have an ostomy, consider joining an ostomy support group or seeking care from a health care professional that specializes in ostomies.
- Acupuncture and/or heat can help relieve some symptoms of nerve damage caused by chemotherapy. Duloxetine may help with painful nerve damage.

7

Making treatment decisions

64 It's your choice

64 Questions to ask

68 Resources



It is important to be comfortable with the cancer treatment you choose. This choice starts with having an open and honest conversation with your doctor.

It's your choice

In shared decision-making, you and your doctors share information, discuss the options, and agree on a treatment plan. It starts with an open and honest conversation between you and your doctor.

Treatment decisions are very personal. What is important to you may not be important to someone else.

Some things that may play a role in your decision-making:

- What you want and how that might differ from what others want
- Your religious and spiritual beliefs
- Your feelings about certain treatments like surgery, chemotherapy, and radiation
- Your feelings about pain or side effects such as nausea and vomiting
- Cost of treatment, travel to treatment centers, and time away from work
- Quality of life and length of life
- How active you are and the activities that are important to you

Think about what you want from treatment. Discuss openly the risks and benefits of specific treatments and procedures. Weigh options and share concerns with your doctor. If you take the time to build a relationship with your doctor, it will help you feel supported

when considering options and making treatment decisions.

Second opinion

It is normal to want to start treatment as soon as possible. While cancer can't be ignored, there is time to have another doctor review your test results and suggest a treatment plan. This is called getting a second opinion, and it's a normal part of cancer care. Even doctors get second opinions!

Things you can do to prepare:

- Check with your insurance company about its rules on second opinions. There may be out-of-pocket costs to see doctors who are not part of your insurance plan.
- Make plans to have copies of all your records sent to the doctor you will see for your second opinion.

Support groups

Many people diagnosed with cancer find support groups to be helpful. Support groups often include people at different stages of treatment. Some people may be newly diagnosed, while others may be finished with treatment. If your hospital or community doesn't have support groups for people with cancer, check out the websites listed in this book.

Questions to ask

Possible questions to ask your doctors are listed on the following pages. Feel free to use these or come up with your own. Be clear about your goals for treatment and find out what to expect from treatment. Keep a notebook handy to record answers to your questions.

Questions about treatment

1. Do you consult NCCN recommendations when considering options?
2. Are you suggesting options other than what NCCN recommends? If yes, why?
3. Do your suggested options include clinical trials? Please explain why.
4. How do my age, health, and other factors affect my options?
5. What if I am pregnant, or planning to become pregnant?
6. What are the benefits and risks of each option? Does any option offer a cure or long-term cancer control?
7. How much will treatment cost? What does my insurance cover?
8. How long do I have to decide about treatment?
9. Who can I call on weekends or non-office hours if I have an urgent problem with my cancer or my cancer treatment?
10. Can you give me a copy of my pathology report and other test results?
11. When will I know the results from my genetic testing or biomarker testing?

Questions about non-metastatic rectal cancer

1. Do I need surgery? If so, what type?
2. Is the cancer locally advanced? If so, will I have total neoadjuvant therapy?
3. How likely is it that surgery will be possible after total neoadjuvant therapy?
4. Which side effects of surgery are most likely?
5. How do I prepare for surgery? Do I have to stop taking any of my medicines? Are there foods I will have to avoid?
6. When will I be able to return to my normal activities?
7. Is home care after treatment needed? If yes, what type?
8. What follow-up testing is needed for my cancer stage?
9. How likely is the cancer to return after treatment? Can I do anything to lower the risk?
10. If the cancer does return, what is the recommended treatment?

Questions about stage IV rectal cancer

1. Where has the cancer spread?
2. Am I a candidate for surgery? If not, is it possible that I'll become a candidate?
3. What treatment will I have before, during, or after surgery?
4. Am I a candidate for treatment with local therapies? Did an interventional oncologist/radiologist review my case?
5. Which systemic therapy regimen do you recommend for me? Why?
6. How will you know if systemic therapy is working? What if it stops working?
7. Does my cancer have any biomarkers? How does this affect my options?
8. What is my prognosis?
9. What can be done to prevent or relieve the side effects of treatment?
10. Am I a candidate for a clinical trial? Do you know of one I can join?

Resources

American Cancer Society

cancer.org/cancer/colon-rectal-cancer.html

Anal Cancer Foundation

analcancerfoundation.org

Bowel Cancer UK

bowelcanceruk.org.uk

Cancer.Net

cancer.net/cancer-types/colorectal-cancer

CancerCare

Cancercare.org

Cancer Hope Network

cancerhopenetwork.org

Cancer Support Community

cancersupportcommunity.org

Colon Cancer Coalition

coloncancercoalition.org

Colon Cancer Foundation

coloncancerfoundation.org

Colon Club

Colonclub.com

Colontown

colontown.org

Colorectal Cancer Alliance

ccalliance.org

Colorectal Cancer Canada

colorectalcancercanada.com

Fight Colorectal Cancer

FightColorectalCancer.org

Global Colon Cancer Association

globalcca.org

HPV Cancers Alliance

hpvalliance.org

Love Your Buns

loveyourbuns.org

National Cancer Institute (NCI)

cancer.gov/types/colorectal

National Coalition for Cancer Survivorship

canceradvocacy.org

PAN Foundation

panfoundation.org

U.S. National Library of Medicine Clinical Trials Database

clinicaltrials.gov



Words to know

abdomen

The belly area between the chest and pelvis.

ablation

A type of local therapy used to destroy tumors in the liver or lungs.

adenocarcinoma

Cancer in cells that line organs and make fluids or hormones.

adenoma

The most common type of polyp and is the most likely to form cancer cells. Also called adenomatous polyp.

anus

The opening at the end of the rectum through which stool leaves the body.

biopsy

Removal of small amounts of tissue or fluid to be tested for disease.

cancer grade

A rating of how quickly a cancer is expected to grow and spread. Cancer grade is based on how abnormal cancer cells look when viewed under a microscope.

cancer stage

A rating of the extent of cancer in the body.

carcinoembryonic antigen (CEA)

A protein that gets released by some tumors and can be detected in blood as a tumor marker.

catheter

A flexible tube inserted in the body to give treatment or drain fluid from the body.

clinical trial

Research on an investigational test or treatment to assess its safety or how well it works.

colon

The hollow organ in which eaten food turns from a liquid into a solid form.

colonoscope

A thin, long tube with a light and camera used to see the colon.

colonoscopy

Insertion of a thin tool into the colon to view or remove tissue.

colostomy

Surgery to connect a part of the colon to the outside of the abdomen and that allows stool to drain into a bag.

complete blood count (CBC)

A test of the number of blood cells in a sample of blood.

computed tomography (CT)

A test that uses x-rays from many angles to make a picture of the inside of the body.

contrast

A substance put into the body to make clearer pictures during imaging tests.

embolization

Blocking blood flow to a tumor using beads that emit either chemotherapy or radiation.

endoscopic polypectomy

Surgery to remove a polyp during a colonoscopy.

enema

Injection of liquid into the rectum to clear the bowel.

esophagus

The tube-shaped digestive organ between the mouth and stomach.

external beam radiation therapy (EBRT)

Treatment with radiation received from a machine outside the body. The most common type of radiation therapy used for rectal cancer.

familial adenomatous polyposis (FAP)

An inherited cancer syndrome that increases the risk of developing colon and rectal cancer.

hereditary non-polyposis colon cancer (HNPCC)

An inherited cancer syndrome that increases the risk of developing colon and rectal cancer. Also called Lynch syndrome.

infertility

The inability to produce children.

infusion

A method of giving drugs slowly through a needle into a vein.

intraoperative radiation therapy (IORT)

Radiation therapy that is given inside the body at the end of an operation.

invasive cancer

Cancer cells have grown into the second layer of the rectum wall.

large bowel

The digestive organ that prepares unused food for leaving the body. Includes the colon and rectum.

laxative

Substances used to clean out the bowel.

lymph nodes

Small groups of special disease-fighting cells located throughout the body.

magnetic resonance imaging (MRI)

A test that uses a magnetic field and radio waves to make pictures of areas inside the body.

metastasectomy

Surgery to remove cancer that has spread far from the first tumor.

metastasis

The spread of cancer cells from the first (primary) tumor to other areas of the body.

mucosa

The innermost layer of the rectal wall.

muscularis propria

The third layer of the rectal wall. Also known as the muscle layer.

mutation

An abnormal change in the instructions within cells for making and controlling cells.

needle biopsy

Removal of tissue or fluid samples from the body with a needle.

noninvasive cancer

Cancer cells have not grown into the second layer of the rectum wall.

observation

A period of testing for cancer growth.

pathologic stage

A rating of the extent of cancer based on the results of surgery.

pathologist

A type of doctor that specializes in testing cells and tissue to find disease.

pedunculated polyp

A polyp shaped like a mushroom with a stalk.

pelvis

The area between the hip bones.

polyp

An abnormal growth on the lining of the colon or rectum.

portal vein embolization

The blood vessel to the liver tumor is blocked causing the healthy part of the liver to grow larger.

progression

The growth or spread of cancer after being tested or treated.

radiation therapy

The use of high-energy rays to destroy cancer cells.

radiologist

A doctor who specializes in reading imaging tests.

rectum

An organ in the digestive system that holds stool until it exits the body through the anus.

recurrence

The return of cancer after a cancer-free period.

sessile polyp

A polyp that is flat.

small bowel

The digestive organ that absorbs nutrients from eaten food.

stool

Unused food passed out of the body; also called feces.

submucosa

The second layer of the rectum wall. Made mostly of connective tissue.

supportive care

Treatment for the symptoms or health conditions caused by cancer or its treatment.

surgical margin

The normal tissue around the edge of a tumor that is removed during surgery.

tumor deposit

The presence of tiny tumors where the lymph drains from the tumor.

NCCN Contributors

This patient guide is based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer, Version 2.2022 – September 20, 2022. It was adapted, reviewed, and published with help from the following people:

Dorothy A. Shead, MS
Senior Director
Patient Information Operations

Erin Vidic, MA
Senior Medical Writer, Patient Information

Laura Phillips
Graphic Art Specialist

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer, Version 2.2022 were developed by the following NCCN Panel Members:

Al B. Benson, III, MD/Chair
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Alan P. Venook, MD/Vice-Chair
UCSF Helen Diller Family
Comprehensive Cancer Center

*Mahmoud M. Al-Hawary, MD
University of Michigan Rogel Cancer Center

*Nilofer Azad, MD
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Yi-Jen Chen, MD, PhD
City of Hope National Medical Center

Kristen K. Ciombor, MD
Vanderbilt-Ingram Cancer Center

Stacey Cohen, MD
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Harry S. Cooper, MD
Fox Chase Cancer Center

Dustin Deming, MD
University of Wisconsin
Carbone Cancer Center

Linda Farkas, MD
UT Southwestern Simmons
Comprehensive Cancer Center

Ignacio Garrido-Laguna, MD, PhD
Huntsman Cancer Institute
at the University of Utah

Jean L. Grem, MD
Fred & Pamela Buffett Cancer Center

Andrew Gunn, MD
O'Neal Comprehensive
Cancer Center at UAB

J. Randolph Hecht, MD
UCLA Jonsson
Comprehensive Cancer Center

*Sarah Hoffe, MD
Moffitt Cancer Center

Joleen Hubbard, MD
Mayo Clinic Cancer Center

Steven Hunt, MD
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

William Jeck, MD
Duke Cancer Institute

Kimberly L. Johung, MD, PhD
Yale Cancer Center/Smilow Cancer Hospital

Natalie Kirilcuk, MD
Stanford Cancer Institute

Smitha Krishnamurthi, MD
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Institute

Wells A. Messersmith, MD
University of Colorado Cancer Center

Jeffrey Meyerhardt, MD, MPH
Dana-Farber Brigham and Women's
Cancer Center

Eric D. Miller, MD, PhD
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Mary F. Mulcahy, MD
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Steven Nurkin, MD, MS
Roswell Park Comprehensive Cancer Center

Michael J. Overman, MD
The University of Texas
MD Anderson Cancer Center

Aparna Parikh, MD
Massachusetts General Hospital
Cancer Center

Hitendra Patel, MD
UC San Diego Moores Cancer Center

Katrina Pedersen, MD, MS
Siteman Cancer Center at Barnes
Jewish Hospital and Washington
University School of Medicine

Elizabeth Raskin, MD
UC Davis Comprehensive Cancer Center

Leonard Saltz, MD
Memorial Sloan Kettering Cancer Center

Charles Schneider, MD
Abramson Cancer Center
at the University of Pennsylvania

David Shibata, MD
The University of Tennessee
Health Science Center

John M. Skibber, MD
The University of Texas
MD Anderson Cancer Center

*Constantinos T. Sofocleous, MD, PhD
Memorial Sloan Kettering Cancer Center

Elena M. Stoffel, MD, MPH
University of Michigan Rogel Cancer Center

Eden Stotsky-Himelfarb, BSN, RN
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Christopher G. Willett, MD
Duke Cancer Institute

NCCN Staff

Kristina Gregory, RN, MSN, OCN
Vice President, Clinical Information Programs

Lisa Gurski, PhD
Manager, Licensed Clinical Content

* Reviewed this patient guide. For disclosures, visit [NCCN.org/disclosures](https://www.nccn.org/disclosures).

NCCN Cancer Centers

Abramson Cancer Center
at the University of Pennsylvania
Philadelphia, Pennsylvania
800.789.7366 • penmedicine.org/cancer

Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute
Cleveland, Ohio
800.641.2422 • UH Seidman Cancer Center
uhhospitals.org/services/cancer-services
866.223.8100 • CC Taussig Cancer Institute
my.clevelandclinic.org/departments/cancer
216.844.8797 • Case CCC
case.edu/cancer

City of Hope National Medical Center
Duarte, California
800.826.4673 • cityofhope.org

Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center
Boston, Massachusetts
617.732.5500 • youhaveus.org
617.726.5130
massgeneral.org/cancer-center

Duke Cancer Institute
Durham, North Carolina
888.275.3853 • dukecancerinstitute.org

Fox Chase Cancer Center
Philadelphia, Pennsylvania
888.369.2427 • foxchase.org

Fred & Pamela Buffett Cancer Center
Omaha, Nebraska
402.559.5600 • unmc.edu/cancercenter

Fred Hutchinson Cancer Center
Seattle, Washington
206.667.5000 • fredhutch.org

Huntsman Cancer Institute
at the University of Utah
Salt Lake City, Utah
800.824.2073 • huntsmancancer.org

Indiana University
Melvin and Bren Simon
Comprehensive Cancer Center
Indianapolis, Indiana
888.600.4822 • www.cancer.iu.edu

Mayo Clinic Cancer Center
Phoenix/Scottsdale, Arizona
Jacksonville, Florida
Rochester, Minnesota
480.301.8000 • Arizona
904.953.0853 • Florida
507.538.3270 • Minnesota
mayoclinic.org/cancercenter

Memorial Sloan Kettering
Cancer Center
New York, New York
800.525.2225 • mskcc.org

Moffitt Cancer Center
Tampa, Florida
888.663.3488 • moffitt.org

O'Neal Comprehensive
Cancer Center at UAB
Birmingham, Alabama
800.822.0933 • uab.edu/onealcancercenter

Robert H. Lurie Comprehensive Cancer
Center of Northwestern University
Chicago, Illinois
866.587.4322 • cancer.northwestern.edu

Roswell Park Comprehensive
Cancer Center
Buffalo, New York
877.275.7724 • roswellpark.org

Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine
St. Louis, Missouri
800.600.3606 • siteman.wustl.edu

St. Jude Children's
Research Hospital/
The University of Tennessee
Health Science Center
Memphis, Tennessee
866.278.5833 • stjude.org
901.448.5500 • uthsc.edu

Stanford Cancer Institute
Stanford, California
877.668.7535 • cancer.stanford.edu

The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute
Columbus, Ohio
800.293.5066 • cancer.osu.edu

The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Baltimore, Maryland
410.955.8964
www.hopkinskimmelfcancercenter.org

The University of Texas
MD Anderson Cancer Center
Houston, Texas
844.269.5922 • mdanderson.org

UC Davis
Comprehensive Cancer Center
Sacramento, California
916.734.5959 • 800.770.9261
health.ucdavis.edu/cancer

UC San Diego Moores Cancer Center
La Jolla, California
858.822.6100 • cancer.ucsd.edu

UCLA Jonsson
Comprehensive Cancer Center
Los Angeles, California
310.825.5268 • cancer.ucla.edu

UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
800.689.8273 • cancer.ucsf.edu

University of Colorado Cancer Center
Aurora, Colorado
720.848.0300 • coloradocancercenter.org

University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan
800.865.1125 • rogelcancercenter.org

University of Wisconsin
Carbone Cancer Center
Madison, Wisconsin
608.265.1700 • uwhealth.org/cancer

UT Southwestern Simmons
Comprehensive Cancer Center
Dallas, Texas
214.648.3111 • utsouthwestern.edu/simmons

Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
877.936.8422 • vicc.org


Yale Cancer Center/
Smilow Cancer Hospital
New Haven, Connecticut
855.4.SMILOW • yalecancercenter.org

Notes

Index

- ablation** 35–36, 39, 51–53, 56
- acupuncture** 59–60, 62
- biomarker** 22–24, 30, 32, 46, 48, 51, 53–55
- BRAF*** 22–24, 51–52, 55
- carcinoembryonic antigen (CEA)** 18, 24, 43, 46–47, 49, 51, 54
- clinical trial** 22, 37–39
- colonoscopy** 8, 16, 24, 41, 43, 46–47, 51, 54
- familial adenomatous polyposis (FAP)** 15, 24
- fertility** 23–24, 34
- HER2*** 22–24, 51, 53
- hereditary non-polyposis colon cancer (HNPCC)** 15
- hormone replacement therapy (HRT)** 60
- immunotherapy** 22, 30, 32, 39, 52–53, 55
- KRAS/NRAS*** 22, 24, 52
- laparoscopic surgery** 29
- low anterior resection (LAR)** 28, 59
- low anterior resection syndrome (LARS)** 59
- Lynch syndrome** 15, 22, 24
- metastasectomy** 35
- microsatellite instability/mismatch repair (MSI/MMR)** 22, 43, 51–53, 55
- ovarian transposition** 23–24
- polypectomy** 8, 41–43, 49
- sexual health** 30, 34, 59
- supportive care** 56
- survivorship** 57–62





Rectal Cancer

2022

NCCN Foundation gratefully acknowledges our advocacy supporters Anal Cancer Foundation, Colorectal Cancer Alliance and Fight Colorectal Cancer and the following corporate supporters for helping to make available these NCCN Guidelines for Patients: Amgen Inc.; Bristol Myers Squibb; Lilly and Company; Sirtex Medical, Inc.; and Taiho Oncology, Inc. NCCN independently adapts, updates and hosts the NCCN Guidelines for Patients. Our corporate supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein.

To support the NCCN Guidelines for Patients

[DONATE NOW](#)

Visit [NCCNFoundation.org/Donate](https://www.nccn.org/Donate)



National Comprehensive
Cancer Network®

3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462
215.690.0300

[NCCN.org/patients](https://www.nccn.org/patients) – For Patients | [NCCN.org](https://www.nccn.org) – For Clinicians